WO1996000574A1 - Vitronectin receptor antagonists - Google Patents

Vitronectin receptor antagonists Download PDF

Info

Publication number
WO1996000574A1
WO1996000574A1 PCT/US1995/008146 US9508146W WO9600574A1 WO 1996000574 A1 WO1996000574 A1 WO 1996000574A1 US 9508146 W US9508146 W US 9508146W WO 9600574 A1 WO9600574 A1 WO 9600574A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
oxo
tetrahydro
amino
acetic acid
Prior art date
Application number
PCT/US1995/008146
Other languages
French (fr)
Inventor
Russell Donovan Cousins
Richard Mcculloch Keenan
Chet Kwon
William Henry Miller
Irene Nijole Uzinskas
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to EP95925353A priority Critical patent/EP0762882A4/en
Priority to JP8503418A priority patent/JPH10504807A/en
Publication of WO1996000574A1 publication Critical patent/WO1996000574A1/en
Priority to US09/679,982 priority patent/US6458784B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Definitions

  • This invention relates to pharmaceutically active compounds which inhibit the vitronectin receptor and are useful for the treatment of osteoporosis. '
  • Bone formation is the result of the deposition of mineralized bone by osteoblast cells
  • bone resorption is the result of the dissolution of bone matrix by osteoclast cells.
  • Many bone diseases are brought about by an imbalance of bone formation relative to bone resorption. For instance, diseases such as osteoporosis are characterized by a net loss of bone matrix. Thus, agents which inhibit bone resorption are useful for the treatment of such diseases.
  • An activated osteoclast resorbs bone by attaching to the bone matrix, and secreting proteolytic enzymes, organic acids and protons into the sealed compartment formed between its cell membrane and the bone matrix.
  • the acidic environment and proteolytic enzymes effect the dissolution of bone in the sealed compartment to create pits, or lacuna, in the bone surface, which are apparent when the osteoclast detaches from the bone.
  • osteoclasts are mediated through cell surface adhesion receptors called integrins.
  • integrins cell surface adhesion receptors
  • the vitronectin receptor, or the ⁇ 3 integrin is known to bind to bone matrix proteins, such as osteopontin, bone sialoprotein and thrombospondin, which contain the tri-peptide Arg-Gly-Asp (or RGD) motif.
  • RGD tri-peptide Arg-Gly-Asp
  • Endocrinology 1993, 132, 1411 has further shown that echistatin inhibits bone resorption in vivo in the rat.
  • EP 528 587 and 528 586 report substituted phenyl derivatives which inhibit osteoclast mediated bone resorption.
  • Bondinell, et al, in WO 93/00095 (PCT/US92/05463) and PCT US93/12436 disclose that certain compounds which have a substituted 6-7 bicyclic ring system are useful for inhibiting the fibrinogen receptor, which is an integrin ( ⁇ i b ⁇ 3 ) protein founds on platelets.
  • Other 6-7 bicyclic ring systems which inhibit the fibrinogen receptor are disclosed by Blackburn et al. in WO 93/08174 (PCT/US92/08788).
  • This invention comprises compounds of the formula (I) as described hereinafter, which have pharmacological activity for the inhibition of the vitronection receptor and are useful in the treatment of osteoporosis.
  • This invention is also a pharmaceutical composition
  • a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically carrier.
  • This invention is also a method of treating diseases which are mediated by ligands which bind to the vitronectin receptor.
  • the compounds of this invention are useful for treating osteoporosis, atherosclerosis, restenosis and cancer.
  • This invention comprises compounds of formula (I):
  • R 1 is H, C ⁇ _6 alkyl or benzyl
  • R2 is (CH 2 )nCO 2 H
  • R 3 is H, C ⁇ _6alkyl, Ar-Co- ⁇ -alkyl, Het-Co_6alkyl, or C3_6cycloalkyl-Co_6alkyl;
  • R 4 is W-U, Y-(CHR 5 )m-U or Z-C(O);
  • R 5 and R 6 are independently chosen from H, C ⁇ _6alkyl, Ar-Co-6alkyl, Het-
  • Co- ⁇ -alkyl and C3_6cycloalkyl-Co_6alkyl; m is 1 or 2; n is 1 or 2; U is NR'QO), C ⁇ NR 1 , CH CH, C ⁇ C, CH 2 -CH 2 , O-CH 2 , CH 2 -O or
  • Rd is H, N(R! 2 , C ⁇ _4alkyl, CONtR ⁇ , OH, OR 1 , or Ar-C 0 -4alkyl
  • R e is H, Ci-4alkyl, Het-Co-4alkyl or Ar-Co ⁇ alkyl; and pharmaceutically acceptable salts thereof, provided that R 3 is not phenylethyl when R 4 is (3-amidino)phenylaminocarbonyl and X-X' is NH-CH.
  • the compounds of formula (I) inhibit the binding of vitronectin and other RGD -containing peptides to the vitronectin ( ⁇ 3) receptor.
  • Inhibition of the vitronectin receptor on osteoclasts inhibits osteoclastic bone resorption and is useful in the treatment of diseases wherein bone resorption is associated with pathology, such as osteoporosis.
  • X-X' is NH-CH or CH 2 -CH.
  • U is NR i CO, CONR l or C ⁇ OCONR 1 . More preferably U is NR i CO.
  • R a is hydroxy or amino.
  • R a is amino.
  • W is Preferably, W is H 2 N or (3-amidino)phenyl.
  • Y is , OH or NHR 6 .
  • R 5 is H, phenyl or C ⁇ _ 6 alkyl.
  • R 6 is benzyl, 2-pyridinyl or H.
  • Z is 1-piperazinyl or 1 -piperidinyl.
  • R 4 is Y-(CH 2 ) m NCH CO.
  • R e is H or substituted or unsubstituted phenyl, benzyl, 2- or 3- pyridinyl, 2- or 4-pyrimidinyl or 1-, 2- or 3-piperidinyl.
  • Z is 1-piperazinyl
  • R e is preferably 2- or 3- pyridinyl or 2- or 4-pyrimidinyl.
  • Z is piperidinyl
  • R e is preferably 1 -piperidinyl.
  • Y is NH 2 or pyridinyl.
  • n is 1.
  • R 1 is H, methyl or phenylethyl.
  • novel compounds of this invention are the following:
  • Ci- 4 _ ⁇ lkyl as applied herein means an optionally substituted alkyl group of 1 to 4 carbon atoms, and includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and t-butyl.
  • Ci-6alkyl additionally includes pentyl, n-pentyl, isopentyl, neopentyl and hexyl and the simple aliphatic isomers thereof.
  • Co-4alkyl and Co_6alkyl additionally indicate that no alkyl group need be present (e.g., that a covalent bond is present).
  • a substituent on a C ⁇ _ 6 alkyl group may be on any carbon atom which results in a stable structure, and is available by conventional synthetic techniques. Suitable substituents are C ⁇ _ 4 alkyl, OR 1 , SR 1 , C ⁇ _ 4 alkyl, Ci- 4 alkylsulfonyl, C ⁇ _ 4 alkylsulfoxyl, -CN, N(R i ) 2 ⁇ CH 2 N(R 1 ) 2 , -NO 2 , -CF 3 , -CO 2 R' 3 -CONCR 1 ⁇ , -COR 1 . -NR i C ⁇ R 1 , OH, F, Cl, Br, I, or CF 3 S(O) r ,wherein r is 0 to 2.
  • Ar, or aryl as applied herein, means phenyl or naphthyl, or phenyl or naphthyl substituted by one to three substituents, such as those defined above for alkyl, especially C ⁇ _ 4 alkyl, C ⁇ _4alkoxy, Ci ⁇ alkthio, trifluoroalkyl, OH, F, Cl, Br, I or a 1,2-methylene dioxy group.
  • Het, or heterocycle indicates an optionally substituted five or six membered monocyclic ring, or a nine or ten-membered bicyclic ring containing one to three heteroatoms chosen from the group of nitrogen, oxygen and sulfur, which are stable and available by conventional chemical synthesis.
  • heterocycles are benzofuryl, benzimidazole, benzopyran, benzothiophene, furan, imidazole, indoline, morpholine, piperidine, piperazine, pyrrole, pyrrolidine, tetrahydropyridine, pyridine, thiazole, thiophene, quinoline, isoquinoline, and tetra- and perhydro- quinoline and isoquinoline. Any accessible combination of up to three substituents on the Het ring, such as those defined above for alkyl that are available by chemical synthesis and are stable are within the scope of this invention.
  • C3-7cycloalkyl refers to an optionally substituted carbocyclic system of three to seven carbon atoms, which may contain up to two unsaturated carbon- carbon bonds.
  • Typical of C 3 _7cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl and cycloheptyl. Any combination of up to three substituents, such as those defined above for alkyl, on the cycloalkyl ring that is available by conventional chemical synthesis and is stable, is within the scope of this invention.
  • Certain radical groups are abbreviated herein.
  • t-Bu refers to the tertiary butyl radical
  • Boc refers to the t-butyloxycarbonyl radical
  • Fmoc refers to the fluorenylmethoxycarbonyl radical
  • Ph refers to the phenyl radical
  • Cbz refers to the benzyloxycarbonyl radical
  • BrZ refers to the o-bromobenzyloxycarbonyl radical
  • C1Z refers to the o-chlorobenzyloxycarbonyl radical
  • Bn refers to the benzyl radical
  • 4-MBzl refers to the 4-methyl benzyl radical
  • Me refers to methyl
  • Et refers to ethyl
  • Ac refers to acetyl
  • Alk refers to C1.4a.kyl
  • Nph refers to 1- or 2-naphthyl
  • cHex refers to cyclohexyl.
  • MeArg is N ⁇ -methyl argin
  • DCC refers to dicyclohexylcarbodiimide
  • DMAP refers to dimethylaminopyridine
  • DIEA refers to diisopropylethylamine
  • EDC refers to N-ethyl-N'(dimethylaminopropyl)- carbodiimide.
  • HOBt refers to 1 -hydroxybenzotriazole
  • THF refers to tetrahydrofuran
  • DMF refers to dimethyl formamide
  • NBS refers to N-bromo- succinimide
  • Pd/C refers to a palladium on carbon catalyst
  • DPPA diphenylphosphoryl azide
  • BOP refers to benzotriazol-1-yloxy- tris(dimethylamino)phosphonium hexafluorophosphate
  • HF refers to hydrofluoric acid
  • TEA refers to triethylamine
  • TFA refers to trifluoroacetic acid
  • PCC refers to pyridinium chlorochromate.
  • EDC and HOBT or SOCl a carboxylic acid
  • SOCl HOBT or SOCl
  • Many additional methods for converting a carboxylic acid to an amide are known, and can be found in standard reference books, such as "Compendium of Organic Synthetic Methods", Vol. I - VI (published by Wiley-Interscience).
  • the methyl ester of 1-2 is hydrolyzed using aqueous base, for example, aqueous LiOH in THF or aqueous NaOH in methanol, and the intermediate carboxylate salt is acidified with a suitable acid, for instance TFA or HC1, to afford the carboxylic acid 1-3.
  • aqueous base for example, aqueous LiOH in THF or aqueous NaOH in methanol
  • the intermediate carboxylate salt is acidified with a suitable acid, for instance TFA or HC1, to afford the carboxylic acid 1-3.
  • a suitable acid for instance TFA or HC1
  • the intermediate carboxylate salt can be isolated, if desired.
  • the protecting group can be removed either prior or subsequently to the ester hydrolysis step, using methods suitable for selective deprotection of the specific protecting group employed. Such methods are described in Green, "Protective Groups in Organic Synthesis"
  • Piperidine-containing compounds such as HI- 3 can be prepared either from a suitably N-protected piperidine derivative, according to the methods described in Schemes I and ⁇ , or from a pyridine precursor, such as HI-l.
  • a pyridine precursor such as HI-l.
  • the pyridine subunit of HI-l can be reduced to the corresponding piperidine group by hydrogenation over a suitable catalyst, preferably PtO 2 , in the presence of acid, such as HC1.
  • the resulting piperidinium salt IH-2 is then converted to compound ⁇ i-3 by the methods described in Scheme I.
  • the core 6-7 fused ring system is prepared from compounds of the general formula (II):
  • Schemes IV - VI Representative methods for preparing the benzodiazepine nucleus are given by Schemes IV - VI.
  • a representative method for preparing a benzazepine nucleus is given by Scheme VII.
  • a representative method for preparing a benzothiazepine is given by Scheme VIII.
  • An benzoxazepine nucleus may be prepared in the same manner as Scheme VIII, except substituting a benzyl alcohol for a benzyl thiol.
  • NBS N-bromosuccinimide
  • Coupling reagents as used herein denote reagents which may be used to form peptide bonds. Typical coupling methods employ carbodiimides, activated anhydrides and esters and acyl halides. Reagents such as EDC, DCC, DPPA, BOP 10. reagent, HOBt, N-hydroxysuccinimide and oxalyl chloride are typical.
  • Coupling methods to form peptide bonds are generally well known to the art.
  • the methods of peptide synthesis generally set forth by Bodansky et al, THE PRACTICE OF PEPTIDE SYNTHESIS, Springer-Verlag, Berlin, 1984, Ali et al. in J. Med. Chem., 29, 984 (1986) and J. Med. Chem., 30, 2291 (1987) are generally 15 illustrative of the technique and are incorporated herein by reference.
  • the amine or aniline is coupled via its free amino group to an appropriate carboxylic acid substrate using a suitable carbodiimide coupling agent, such as ⁇ , ⁇ ' dicyclohexyl carbodiimide (DCC), optionally in the presence of catalysts such as 1-hydroxybenzotriazole (HOBt) and dimethylamino pyridine 20 (DMAP).
  • a suitable carbodiimide coupling agent such as ⁇ , ⁇ ' dicyclohexyl carbodiimide (DCC)
  • catalysts such as 1-hydroxybenzotriazole (HOBt) and dimethylamino pyridine 20 (DMAP).
  • HABt 1-hydroxybenzotriazole
  • DMAP dimethylamino pyridine 20
  • Other methods such as the formation of activated esters, anhydrides or acid halides, of the free carboxyl of a suitably protected acid substrate, and subsequent reaction with the free amine of a suitably protected amine, optionally in the presence of a base, are also suitable
  • a protected Boc-amino acid or Cbz-amidino benzoic acid is treated in an anhydrous solvent, such as methylene chloride or tetrahydrofuran(THF), in the presence of a base, such as N-methyl morpholine, DMAP or a trialkylamine, with isobutyl chloroformate to form the "activated anhydride", which is subsequently reacted with the free amine of a second protected amino acid or aniline.
  • anhydrous solvent such as methylene chloride or tetrahydrofuran(THF)
  • a base such as N-methyl morpholine, DMAP or a trialkylamine
  • Acid addition salts of the compounds are prepared in a standard manner in a suitable solvent from the parent compound and an excess of an acid, such as hydrochloric, hydrobromic, hydrofluoric, sulfuric, phosphoric, acetic, trifluoroacetic, maleic, succinic or methanesulfonic. Certain of the compounds form inner salts or zwitterions which may be acceptable.
  • Cationic salts are prepared by treating the parent compound with an excess of an alkaline reagent, such as a hydroxide, carbonate or alkoxide, containing the appropriate cation; or with an appropriate organic amine. Cations such as Li + , Na + , K + , Ca ++ , Mg ++ and NH4" 1 " are specific examples of cations present in pharmaceutically acceptable salts.
  • compositions of the compounds of formula (I) may be used in the manufacture of a medicament.
  • Pharmaceutical compositions of the compounds of formula (I) prepared as hereinbefore described may be formulated as solutions or lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use.
  • the liquid formulation may be a buffered, isotonic, aqueous solution. Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution.
  • Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as polyvinylpyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate. Alternately, these compounds may be encapsulated, tableted or prepared in a emulsion or syrup for oral administration. Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition.
  • Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin.
  • Liquid carriers include syrup, peanut oil, olive oil, saline and water.
  • the carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
  • the amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage unit.
  • the pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms.
  • a liquid carrier When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension.
  • Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.
  • the compounds of this invention may also be combined with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository.
  • the compounds described herein are antagonists of the vitronectin receptor, and are useful for treating diseases wherein the underlying pathology is attributable to ligand or cell which interacts with the vitronectin receptor. For instance, these compounds are useful for the treatment of diseases wherein loss of the bone matrix creates pathology.
  • the instant compounds are useful for the treatment of ostoeporosis, hyperparathyroidism, Paget's disease, hypercalcemia of malignancy, osteolytic lesions produced by bone metastasis, bone loss due to immobilization or sex hormone deficiency.
  • the compounds of this invention are also believed to have utility as antitumor, ant ⁇ nflammatory, anti-angiogenic and anti-metastatic agents, and be useful in the treatment of cancer, atherosclerosis and restenosis.
  • the peptide is administered either orally or parenterally to the patient, in a manner such that the concentration of drug is sufficient to inhibit bone resorption, or other such indication.
  • the pharmaceutical composition containing the peptide is administered at an oral dose of between about 0.1 to about 50 mg/kg in a manner consistent with the condition of the patient. Preferably the oral dose would be about 0.5 to about 20 mg/kg.
  • parenteral administration is preferred.
  • An intravenous infusion of the peptide in 5% dextrose in water or normal saline, or a similar formulation with suitable excipients, is most effective, although an intramuscular bolus injection is also useful.
  • the parenteral dose will be about 0.01 to about 100 mg/kg; preferably between 0.1 and 20 mg/kg.
  • the compounds are administered one to four times daily at a level to achieve a total daily dose of about 0.4 to about 400 mg/kg/day.
  • the precise level and method by which the compounds are administered is readily determined by one routinely skilled in the art by comparing the blood level of the agent to the concentration required to have a therapeutic effect.
  • the compounds may be tested in one of several biological assays to determine the concentration of compound which is required to have a given pharmacological effect.
  • Solid-Phase [ 3 H]-SK&F-107260 Binding to cc v ⁇ 3 Human placenta or human platelet ⁇ v ⁇ 3 (0.1-0.3 mg/mL) in buffer T (containing 2 mM CaCl 2 and 1% octylglucoside) was diluted with buffer T containing 1 mM CaCl 2 , 1 mM MnCl 2 , 1 mM MgCl 2 (buffer A) and 0.05% NaN 3 , and then immediately added to 96-well ELISA plates (Corning, New York, NY) at 0.1 mL per well. 0.1 - 0.2 ⁇ g of ⁇ v ⁇ 3 was added per well.
  • the plates were incubated overnight at 4°C. At the time of the experiment, the wells were washed once with buffer A and were incubated with 0.1 mL of 3.5% bovine serum albumin in the same buffer for 1 hr at room temperature. Following incubation the wells were aspirated completely and washed twice with 0.2 mL buffer A.
  • the IC 50 concentration of the antagonist to inhibit 50% binding of [ 3 H]-SK&F- 107260
  • the Kj dissociation constant of the antagonist
  • Ki IC 50 /(1 + IJK d )
  • L and K d were the concentration and the dissociation constant of [ 3 H]-SK&F- 107260, respectively.
  • Compounds of the present invention inhibit vitronectin binding to SK&F 107260 in the concentration range of 0.1 to 25 micromolar.
  • Preferred compounds inhibit vitronectin binding at a concentration of less than 1 micromolar.
  • Each experimental group consists of 5-6 male Sprague-Dawley rats.
  • the rats are parathyroidectomized (by the vendor, Taconic Farms) 7 days prior to use. Twenty four hours prior to use, circulating ionized calcium levels are measured in whole blood immediately after it has been withdrawn by tail venipuncture into heparinized tubes. Rats are included if ionized Ca level (measured with a Ciba-Corning model 634 calcium pH analyzer) is ⁇ 1.2 mM/L. The rats are then put on a diet of calcium-free chow and deionized water. At the start of the experiment the rats weigh approximately lOOg.
  • Baseline Ca levels are measured and the rats are administered control vehicle (saline) or compound (dissolved in saline) as a single intravenous (tail vein) bolus injection followed immediately by a single subcutaneous injection of either human parathyroid hormone 1-34 peptide (hPTHl-34, dose 0.2mg/kg in saline/0.1% bovine serum albumen, Bachem, Ca) or the PTH vehicle.
  • hPTHl-34 human parathyroid hormone 1-34 peptide
  • the calcemic response to PTH is measured 2h after compound/PTH administration.
  • Each experimental group consists of 8-10 male Sprague-Dawley or Wistar rats of approximately 30-40g body weight at the start of the experiment.
  • the agent being tested is administered by an appropriate route as single or multiple daily doses for a period of seven days.
  • the rats Prior to administration of the first dose, the rats are given a single dose of a fluorescent marker (tetracycline 25mg/kg, or calcein lOmg/kg) that labels the position of bone forming surfaces at that point in time.
  • a fluorescent marker tetracycline 25mg/kg, or calcein lOmg/kg
  • the rats are killed and both forelimbs are removed at the elbow, the foot is removed at the ankle and the skin removed.
  • the sample is frozen and mounted vertically on a microtome chuck.
  • the rate of bone resorption is measured morphometrically in the medial-dorsal portion of the cortical bone. The measurement is done as follows: the amount of bone resorbed at the periosteal surface is equal to the distance by which the periosteal surface has advanced towards the fluorescent label which had been incorporated at the endosteal bone formation surface on day zero; this distance is calculated by subtracting the width of bone between the label and the periosteal surface on day 7 from the width on day zero; the resorption rate in microns per day is calculated by dividing the result by 7.
  • the cells are washed x2 with cold RPMI-1640 by centrifugation (lOOOrpm, 5 mins at 4°C) and the cells are transferred to a sterile 15 ml centrifuge tube. The number of mononuclear cells are enumerated in an improved Neubauer counting chamber.
  • Sufficient magnetic beads (5 / mononuclear cell), coated with goat anti-mouse IgG, are removed from their stock bottle and placed into 5 ml of fresh medium (this washes away the toxic azide preservative). The medium is removed by immobilizing the beads on a magnet and is replaced with fresh medium.
  • the beads are mixed with the cells and the suspension is incubated for 30 mins on ice. The suspension is mixed frequently.
  • the bead-coated cells are immobilized on a magnet and the remaining cells (osteoclast-rich fraction) are decanted into a sterile 50 ml centrifuge tube.
  • Fresh medium is added to the bead-coated cells to dislodge any trapped osteoclasts. This wash process is repeated xlO. The bead-coated cells are discarded.
  • the osteoclasts are enumerated in a counting chamber, using a large-bore disposable plastic pasteur to charge the chamber with the sample. • The cells are pelleted by centrifugation and the density of osteoclasts adjusted to 1.5xl0 4 /ml in EMEM medium, supplemented with 10% fetal calf serum and 1.7g/litre of sodium bicarbonate.
  • the slices are washed in phosphate buffered saline and fixed in 2% gluteraldehyde (in 0.2M sodium cacodylate) for 5 mins.
  • the column was washed with 50 mL cold buffer A.
  • the lectin-retained GPIIb-IIIa was eluted with buffer A containing 10% dextrose. All procedures were performed at 4°C.
  • the GPIIb-IIIa obtained was >95% pure as shown by SDS polyacrylamide gel electrophoresis.
  • a mixture of phosphatidylserine (70%) and phosphatidylcholine (30%) (Avanti Polar Lipids) were dried to the walls of a glass tube under a stream of nitrogen.
  • Purified GP ⁇ b- ⁇ la was diluted to a final concentration of 0.5 mg/mL and mixed with the phospholipids in a protein:phospholipid ratio of 1:3 (w:w). The mixture was resuspended and sonicated in a bath sonicator for 5 min.
  • the mixture was then dialyzed overnight using 12,000-14,000 molecular weight cutoff dialysis tubing against a 1000-fold excess of 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 2 mM CaC12 (with 2 changes).
  • the GPIIb-IIIa-containing liposomes wee centrifuged at 12,000g for 15 min and resuspended in the dialysis buffer at a final protein concentration of approximately 1 mg/mL. The liposomes were stored at -70C until needed.
  • GPIIb-IIIa The binding to the fibrinogen receptor (GPIIb-IIIa) was assayed by an indirect competitive binding method using [ 3 H]-SK&F- 107260 as an RGD-type ligand.
  • the binding assay was performed in a 96-well filtration plate assembly (Millipore Corporation, Bedford, MA) using 0.22 um hydrophilic durapore membranes.
  • the wells were precoated with 0.2 mL of 10 ⁇ g/mL polylysine (Sigma Chemical Co., St. Louis, MO.) at room temperature for 1 h to block nonspecific binding.
  • Various concentrations of unlabeled benzadiazapines were added to the wells in quadruplicate.
  • [ 3 H]-SK&F- 107260 was applied to each well at a final concentration of 4.5 nM, followed by the addition of 1 ⁇ g of the purified platelet GPHb- ⁇ ia-containing liposomes. The mixtures were incubated for 1 h at room temperature. The GPIIb-IIIa-bound [3HJ-SK&F- 107260 was seperated from the unbound by filtration using a Millipore filtration manifold, followed by washing with ice-cold buffer (2 times, each 0.2 mL).
  • IC50 concentration of the antagonist which inhibits specific binding of [ 3 H]-SK&F-107260 by 50% at equilibrium.
  • Preferred compounds of this invention have an affinity for the vitronectin receptor relative to the fibrinogen receptor of greater than 3:1. More preferred compounds have a ratio of activity of greater than 10:1.
  • Table 1 The comparative results of the enhanced binding of the compounds of this invention to the vitronecton receptor relative to the fibrinogen receptor are given in Table 1 below:
  • the compounds of the instant invention were tested for their ability to inhibit the migration and proliferation of smooth muscle tissue in an artery or vein in order to assess their ability to prevent restenosis of an artery, such as that which typically occurs following angioplasty.
  • Rat or human aortic smooth muscle cells were used. The cell migration was monitored in a Transwell cell culture chamber by using a polycarbonate membrane with pores of 8 urn (Costar). The lower surface of the filter was coated with vitronectin. Cells were suspended in DMEM supplemented with 0.2% bovine serum albumin at a concentration of 2.5 - 5.0 x 10 6 cells/mL, and were pretreated with test compound at various concentrations for 20 min at 20°C. The solvent alone was used as control. 0.2 mL of the cell suspension was placed in the upper compartment of the chamber. The lower compartment contained 0.6 mL of DMEM supplemented with 0.2% bovine serum albumin.
  • Incubation was carried out at 37 °C in an atmosphere of 95% air/5% CO 2 for 24 hr. After incubation, the non- migrated cells on the upper surface of the filter were removed by gentle scraping. The filter was then fixed in methanol and stained with 10% Giemsa stain. Migration was measured either by a) counting the number of cells that had migrated to the lower surface of the filter or by b) extracting the stained cells with 10% acetic acid followed by determining the absorbance at 600 nM.
  • Nuclear magnetic resonance spectra were recorded at either 250 or 400 MHz using, respectively, a Bruker AM 250 or Bruker AC 400 spectrometer.
  • CDCI 3 is deuteriochloroform
  • DMSO-d ⁇ is hexadeuteriodimethylsulfoxide
  • CD 3 OD is tetradeuteriomethanol. Chemical shifts are reported in parts per million (5) downfield from the internal standard tetramethylsilane.
  • ODS refers to an octadecylsilyl derivatized silica gel chromatographic support. 5 ⁇ Apex-ODS indicates an octadecylsilyl derivatized silica gel chromatographic support having a nominal particle size of 5 ⁇ , made by Jones Chromatography, Littleton, Colorado.
  • YMC ODS-AQ® is an ODS chromatographic support and is a registered trademark of YMC Co. Ltd., Kyoto, Japan.
  • PRP-1® is a polymeric (styrene-divinylbenzene) chromatographic support, and is a registered trademark of Hamilton Co., Reno, Nevada.
  • Celite® is a filter aid composed of acid-washed diatomaceous silica, and is a registered trademark of Manville Corp., Denver, Colorado.
  • Methyl ( ⁇ )-8-carboxy-2-methyl-3-oxo-2,3,4,5-tetrahaydro-lH-2- benzazepine-4-acetate was prepared by the method disclosed in Example 1 of WO 94/14776, except substituting 4-bromo-3-methylbenzoic acid for 3-bromo-4- methylbenzoic acid and substituting methylamine for phenethylamine therein.
  • 4-(2-Methylpyridyl) piperazine was prepared by the procedure of Cross and Dickinson, US 4,806,536 (Feb. 21, 1989).
  • reaction mixture was partitioned between CH2CI2 (150 mL) and 5% NaHCO3 (70 mL). The organic layer was separated, washed sequentially with 5% NaHCO3 (50 mL) and H2O (50 mL), dried (Na2SO4), and concentrated to leave a yellowish solid (0.69 g).
  • Methyl 2-(2-pyridinyl)aminoacetate hydrochloride (1.0 g, 5 mmol) was partitioned between EtOAc and 10% K 2 CO 3 . The organic layer was washed with brine, dried (MgSO 4 ), and concentrated. The residue was dissolved in CH 2 C1 2 (10 mL), and di-tert-butyl dicarbonate (1.2 g, 5 mmol) was added. The reaction was stirred at RT under argon overnight, then was concentrated.
  • Methyl 2-(N-tert-butoxycarbonyl-N-2-pyridinyl)aminoacetate was saponified according to the procedure of Example 6(b) to give the title compound (74%) as a white solid.
  • Methyl ( ⁇ )-8-[(2-[tert-butoxycarbonyl]aminoacetyl)amino]-2-methyl-3-oxo- 2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetate was saponified according to the procedure of example 6(b). The resulting product was stirred in 1 : 1 CH2CI2/TFA for 2 h, then was concentrated.

Abstract

Compounds of formula (I) are disclosed which are inhibitors of the vitronectin receptor, wherein X-X' is NR1-CH, NC(O)R3-CH, N=C, CR?1=C, CHR1¿-CH, O-CH or S-CH; R1 is H, C¿1-6?alkyl or benzyl; R?2¿ is (CH¿2?)nCO2H; R?3¿ is H, C¿1-6?alkyl, Ar-C0-6alkyl, Het-C0-6 alkyl, or C3-6cycloalkyl-C0-6alkyl; R?4¿ is W-U, Y-(CHR5)m-U or Z-C(O); R?5 and R6¿ are independently chosen from H, C¿1-6?alkyl, Ar-C0-6alkyl;, Het-C0-6alkyl and C3-6cycloalkyl-C0-6alkyl; m is 1 or 2; n is 1 or 2; U is NR?1¿C(O), C(O)NR1, CH=CH, C C, CH¿2?-CH2, O-CH2, CH2-O or CH2OCONR?1¿; W is (a), (b) or (c); Ra is H, OH, NO¿2?, N(R?6)¿2, CON(R6)2, CH2N(R6)2, or R6HN-C(=NH); Y is NH¿2?, NHR?6, N(R6)¿2, C(O)N(R6)2, OH, =N-OR6, (d), (e) or (f); Z is (g) or (h); Rd is H, N(R1)2, C1-4alkyl, CON(R1)2, OH, OR1, or Ar-C¿0-4?alkyl; R?e¿ is H, C¿1-4?alkyl, 2- or 3-pyridinyl, 1-, 2- or 3-piperidinyl, or 2- or 4-pyrimidinyl; and pharmaceutically acceptable salts thereof.

Description

TITLE
Vitronectin Receptor Antagonists
FIELD OF THE INVENTION
This invention relates to pharmaceutically active compounds which inhibit the vitronectin receptor and are useful for the treatment of osteoporosis. '
BACKGROUND OF THE INVENTION Mammalian bone is constantly undergoing bone remodeling, which is a dynamic process of bone resorption and bone formation. These processes are mediated by specialized cell types: bone formation is the result of the deposition of mineralized bone by osteoblast cells, and bone resorption is the result of the dissolution of bone matrix by osteoclast cells. Many bone diseases are brought about by an imbalance of bone formation relative to bone resorption. For instance, diseases such as osteoporosis are characterized by a net loss of bone matrix. Thus, agents which inhibit bone resorption are useful for the treatment of such diseases. An activated osteoclast resorbs bone by attaching to the bone matrix, and secreting proteolytic enzymes, organic acids and protons into the sealed compartment formed between its cell membrane and the bone matrix. The acidic environment and proteolytic enzymes effect the dissolution of bone in the sealed compartment to create pits, or lacuna, in the bone surface, which are apparent when the osteoclast detaches from the bone.
Recent studies have indicated that the attachment of osteoclasts to the bone matrix is mediated through cell surface adhesion receptors called integrins. For instance, Davies, et al, J. Cell Biol, 1989, 109, 1817, disclose that the osteoclast functional antigen, which is implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor. The vitronectin receptor, or the αγβ3 integrin, is known to bind to bone matrix proteins, such as osteopontin, bone sialoprotein and thrombospondin, which contain the tri-peptide Arg-Gly-Asp (or RGD) motif. Thus, Horton, et al, Exp. Cell Res. 1991, 195, 368, disclose that RGD-containing peptides and an anti-vitronectin receptor antibody (23C6) inhibit dentine resorption and cell spreading by osteoclasts. In addition, Sato, et al, J. Cell Biol. 1990, 111, 1713 disclose that echistatin, a snake venom peptide which contains the RGD sequence, is a potent inhibitor of bone resorption in tissue culture, and inhibits attachment of osteoclasts to bone. Fisher, et al,
Endocrinology 1993, 132, 1411, has further shown that echistatin inhibits bone resorption in vivo in the rat. EP 528 587 and 528 586 report substituted phenyl derivatives which inhibit osteoclast mediated bone resorption.
Bondinell, et al, in WO 93/00095 (PCT/US92/05463) and PCT US93/12436 disclose that certain compounds which have a substituted 6-7 bicyclic ring system are useful for inhibiting the fibrinogen receptor, which is an integrin (αιibβ3) protein founds on platelets. Other 6-7 bicyclic ring systems which inhibit the fibrinogen receptor are disclosed by Blackburn et al. in WO 93/08174 (PCT/US92/08788). It has now been discovered that certain appropriately substituted 1 ,4-benzodiazepine, -benzothiazepine, -benzoxazepine and 2- benzazepine compounds are potent inhibitors of the vitronectin receptor. In particular, it has been discovered that certain such compounds are suprisingly more potent inhibitors of the vitronectin receptor than the fibrinogen receptor and consequently are more useful in the treatment of diseases such as osteoporosis, cancer, atherosclerosis and for inhibiting restenosis of an artery.
SUMMARY OF THE INVENTION
This invention comprises compounds of the formula (I) as described hereinafter, which have pharmacological activity for the inhibition of the vitronection receptor and are useful in the treatment of osteoporosis.
This invention is also a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically carrier.
This invention is also a method of treating diseases which are mediated by ligands which bind to the vitronectin receptor. In a particular aspect, the compounds of this invention are useful for treating osteoporosis, atherosclerosis, restenosis and cancer. DETAILED DESCRIPTION
This invention comprises compounds of formula (I):
Figure imgf000005_0001
α) wherein
X-X' is NR!-CH, NC(O)R3-CH, N=C, CRΪ=C, CHRi-CH, O-CH or S-CH;
R1 is H, Cι_6 alkyl or benzyl;
R2 is (CH2)nCO2H;
R3 is H, Cι_6alkyl, Ar-Co-ό-alkyl, Het-Co_6alkyl, or C3_6cycloalkyl-Co_6alkyl;
R4 is W-U, Y-(CHR5)m-U or Z-C(O);
R5 and R6 are independently chosen from H, Cι_6alkyl, Ar-Co-6alkyl, Het-
Co-ό-alkyl and C3_6cycloalkyl-Co_6alkyl; m is 1 or 2; n is 1 or 2; U is NR'QO), C^NR1, CH=CH, C≡ C, CH2-CH2, O-CH2, CH2-O or
CH^CONR1;
Figure imgf000005_0002
R- is H, OH, NO2, N(R6)2, CON(R6)2, CH2N(R6)2, or R6HN-C(=NH);
Y is NH2, NHR6, N(R6)2, C(O)N(R6)2, OH, =N-OR6,
Figure imgf000005_0003
Figure imgf000005_0004
Rd is H, N(R!)2, Cι_4alkyl, CONtR^, OH, OR1, or Ar-C0-4alkyl; Re is H, Ci-4alkyl, Het-Co-4alkyl or Ar-Co^alkyl; and pharmaceutically acceptable salts thereof, provided that R3 is not phenylethyl when R4 is (3-amidino)phenylaminocarbonyl and X-X' is NH-CH.
The compounds of formula (I) inhibit the binding of vitronectin and other RGD -containing peptides to the vitronectin (αγβ3) receptor. Inhibition of the vitronectin receptor on osteoclasts inhibits osteoclastic bone resorption and is useful in the treatment of diseases wherein bone resorption is associated with pathology, such as osteoporosis.
Suitably, X-X' is NH-CH or CH2-CH.
Preferably, U is NRiCO, CONRl or C^OCONR1. More preferably U is NRiCO.
Suitably Ra is hydroxy or amino. Preferably Ra is amino.
Suitably W is
Figure imgf000006_0001
Preferably, W is H2N or (3-amidino)phenyl.
Suitably Y is
Figure imgf000006_0002
, OH or NHR6. Suitably R5 is H, phenyl or Cι_6alkyl. Suitably R6 is benzyl, 2-pyridinyl or H. Suitably Z is 1-piperazinyl or 1 -piperidinyl. Suitably R4 is Y-(CH2)mNCH CO.
Suitably Re is H or substituted or unsubstituted phenyl, benzyl, 2- or 3- pyridinyl, 2- or 4-pyrimidinyl or 1-, 2- or 3-piperidinyl. When Z is 1-piperazinyl, Re is preferably 2- or 3- pyridinyl or 2- or 4-pyrimidinyl. When Z is piperidinyl, Re is preferably 1 -piperidinyl.
Preferably Y is NH2 or pyridinyl. Preferably n is 1.
Preferably R1 is H, methyl or phenylethyl. Representative of the novel compounds of this invention are the following:
(±)-7-[[(6-Amino-2-pyridinyl)amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-
1H- 1 ,4-benzodiazepine-2-acetic acid; (±)-8-[[(6-amino-2-pyridinyl)amino]carbonyl]-2-methyl-3-oxo-2,3,4,5-tetrahydro- lH-2-benzazepine-4- acetic acid; (±)-7-[[(6-amino-3-pyridinyl)amino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5- tetrahydro- 1 H- 1 ,4-benzodiazepine-2-acetic acid ; (±)-l-Acetyl-7-[[(6-amino-2-pyridinyl)amino]carbonyl]-4-methyl-3-oxo-2,3,4,5- tetrahydro- 1 H- 1 ,4-benzodiazepine-2-acetic acid ; (±)-2-methyl-3-oxo-8-[[2-(pyridinyl)carbonyl]amino]-2,3,4,5-tetrahydro-lH-2- benzazepine-4-acetic acid; (±)-8-[(benzyloxycarbonyl)amino]-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2- benzazepine-4-acetic acid; (±)-7-[[[3-(aminoiminomethyl)phenyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5- tetrahydro- 1 H- 1 ,4-benzodiazepine-2-acetic acid ; (±)-7-[[[3-(aminocarbonyl)phenyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5- tetrahydro- 1 H- 1 ,4-benzodiazepine-2-acetic acid ; (±)-4-methyl-3-oxo-7-[l-(4-phenylpiperazinyl)carbonyl]-2,3,4,5-tetrahydro-lH- l,4-benzodiazepine-2-acetic acid;
(±)-4-methyl-3-oxo-7-[( 1 -piperazinyl)carbonyl]-2,3,4,5-tetrahydro- 1 H- 1 ,4- benzodiazepine-2-acetic acid; (±)-4-methyl-3-oxo-7-[l-[4-(l-piperidinyl)piperidinyl]carbonyl]-2,3,4,5-tetrahydro-
1H- 1 ,4-benzodiazepine-2-acetic acid; (±)-4-methyl-3-oxo-7-[l-[4-(2-pyridinyl)piperazinyl]carbonyl]-2,3,4,5-tetrahydro-
1H- 1 ,4-benzodiazepine-2-acetic acid; (±)-4-methyl-3-oxo-7-[l-[4-(phenylmethyl)piperazinyl]carbonyl]-2,3,4,5- tetrahydro- 1 H- 1 ,4-benzodiazepine-2-acetic acid; (±)-4-methyl-3-oxo-7-[l-[4-(2-pyrimidinyl)piperazinyl]carbonyl]-2,3,4,5- tetrahydro- 1 H- 1 ,4-benzodiazepine-2-acetic acid;
8-[[2S-amino-3-phenylpropanoyl]amino]-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2- benzazepine-4RS-acetic acid; (±)-8-[[[(2-hydroxy-2-phenyl)ethyl]methylamino]carbonyl]-2-methyl-3-oxo-
2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetic acid; (±)-7-[[[N-(2-hydroxyethyl)-N-methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5- tetrahydro- 1H- 1 ,4-benzodiazepine-2-acetic acid; (±)-8-[[(2-(2-pyridinylamino)acetyl]amino]-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-
2-benzazepine-4-acetic acid; (±)-4-methyl-3-oxo-7-[[(2-phenylaminoethyl)amino]carbonyl]-2,3,4,5-tetrahydro- lH-l,4-benzodiazepine-2-acetic acid;
(±)-8-[(2-aminoacetyl)amino]-2-methyl-3-oxo-2,3,4,5-tetrahydro-lh-2- benzazepine-4-acetic acid; (+/-)-8-[(3-aminopropanoyl)amino]-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2- benzazepine-4-acetic acid; and (±)-4-methyl-3-oxo-7-[[[(3-pyridinyl)methyl]amino]carbonyl]-2,3,4,5-tetrahydro-
1H- 1 ,4-benzodiazepine-2-acetic acid; Other compounds useful in the method of inhibiting the vitronectin receptor are: (±)-7-[[[3-(Aminoiminomethyl)phenyl]amino]carbonyl]-3-oxo-4-(2-phenylethyl)-
2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid. (±)-7-[l-[4-(2-Methyl-4-pyridinyl)piperazinyl]carbonyl]-4-methyl-3-oxo- 2,3,4,5- tetrahydro- 1 H- 1 ,4-benzodiazepine-2-acetic acid ; (±)-3-Oxo-4-(2-phenylethyl)-7-[l-[4-(4-pyridinyl)piperazinyl]carbonyl]-2,3,4,5- tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; and (±)-4-Methyl-3-oxo-7-[l-[4-(4-pyridinyl)piperazinyl]carbonyl]-2,3,4,5-tetrahydro- 1H- 1 ,4-benzodiazepine-2-acetic acid.
Abbreviations and symbols commonly used in the peptide and chemical arts are used herein to describe the compounds of this invention. In general, the amino acid abbreviations follow the IUPAC-IUB Joint Commission on Biochemical Nomenclature as described in Eur. J. Biochem., 158, 9 (1984).
Ci-4_ιlkyl as applied herein means an optionally substituted alkyl group of 1 to 4 carbon atoms, and includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and t-butyl. Ci-6alkyl additionally includes pentyl, n-pentyl, isopentyl, neopentyl and hexyl and the simple aliphatic isomers thereof. Co-4alkyl and Co_6alkyl additionally indicate that no alkyl group need be present (e.g., that a covalent bond is present).
A substituent on a Cι_6 alkyl group, may be on any carbon atom which results in a stable structure, and is available by conventional synthetic techniques. Suitable substituents are Cι_4alkyl, OR1, SR1, Cι_4alkyl, Ci-4alkylsulfonyl, Cι_4alkylsulfoxyl, -CN, N(Ri)2ι CH2N(R1)2, -NO2, -CF3, -CO2R'3 -CONCR1^, -COR1. -NRiC^R1, OH, F, Cl, Br, I, or CF3S(O)r,wherein r is 0 to 2.
Ar, or aryl, as applied herein, means phenyl or naphthyl, or phenyl or naphthyl substituted by one to three substituents, such as those defined above for alkyl, especially Cι_4alkyl, Cι_4alkoxy, Ci^alkthio, trifluoroalkyl, OH, F, Cl, Br, I or a 1,2-methylene dioxy group.
Het, or heterocycle, indicates an optionally substituted five or six membered monocyclic ring, or a nine or ten-membered bicyclic ring containing one to three heteroatoms chosen from the group of nitrogen, oxygen and sulfur, which are stable and available by conventional chemical synthesis. Illustrative heterocycles are benzofuryl, benzimidazole, benzopyran, benzothiophene, furan, imidazole, indoline, morpholine, piperidine, piperazine, pyrrole, pyrrolidine, tetrahydropyridine, pyridine, thiazole, thiophene, quinoline, isoquinoline, and tetra- and perhydro- quinoline and isoquinoline. Any accessible combination of up to three substituents on the Het ring, such as those defined above for alkyl that are available by chemical synthesis and are stable are within the scope of this invention.
C3-7cycloalkyl refers to an optionally substituted carbocyclic system of three to seven carbon atoms, which may contain up to two unsaturated carbon- carbon bonds. Typical of C3_7cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl and cycloheptyl. Any combination of up to three substituents, such as those defined above for alkyl, on the cycloalkyl ring that is available by conventional chemical synthesis and is stable, is within the scope of this invention. Certain radical groups are abbreviated herein. t-Bu refers to the tertiary butyl radical, Boc refers to the t-butyloxycarbonyl radical, Fmoc refers to the fluorenylmethoxycarbonyl radical, Ph refers to the phenyl radical, Cbz refers to the benzyloxycarbonyl radical, BrZ refers to the o-bromobenzyloxycarbonyl radical, C1Z refers to the o-chlorobenzyloxycarbonyl radical, Bn refers to the benzyl radical, 4-MBzl refers to the 4-methyl benzyl radical, Me refers to methyl, Et refers to ethyl, Ac refers to acetyl, Alk refers to C1.4a.kyl, Nph refers to 1- or 2-naphthyl and cHex refers to cyclohexyl. MeArg is Nα-methyl arginine. Tet refers to 5- tetrazolyl.
Certain reagents are abbreviated herein. DCC refers to dicyclohexylcarbodiimide, DMAP refers to dimethylaminopyridine, DIEA refers to diisopropylethylamine, EDC refers to N-ethyl-N'(dimethylaminopropyl)- carbodiimide. HOBt refers to 1 -hydroxybenzotriazole, THF refers to tetrahydrofuran, DMF refers to dimethyl formamide, NBS refers to N-bromo- succinimide, Pd/C refers to a palladium on carbon catalyst, DPPA refers to diphenylphosphoryl azide, BOP refers to benzotriazol-1-yloxy- tris(dimethylamino)phosphonium hexafluorophosphate, HF refers to hydrofluoric acid, TEA refers to triethylamine, TFA refers to trifluoroacetic acid, PCC refers to pyridinium chlorochromate.
Compounds of the formula (I) are prepared by the general methods described in Schemes I-IH Scheme I
Figure imgf000010_0001
a) EDC, HOBT, (i-Pr)2NEt, DMF, 2-aminopyridine; b) SOCl2, reflux; c) 2-2- aminopyridine, pyridine, CH2C12; d) 1.0 N LiOH, aqueous THF; e) acidification.
Methyl (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH- 1,4- benzodiazepine-2-acetate (1-1), prepared as described by Bondinell, et al. (WO 93/00095), is converted to an activated form of the carboxylic acid using, for example, EDC and HOBT or SOCl , and the activated form is subsequently reacted with an appropriate amine to afford the corresponding amide 1-2. Many additional methods for converting a carboxylic acid to an amide are known, and can be found in standard reference books, such as "Compendium of Organic Synthetic Methods", Vol. I - VI (published by Wiley-Interscience). The methyl ester of 1-2 is hydrolyzed using aqueous base, for example, aqueous LiOH in THF or aqueous NaOH in methanol, and the intermediate carboxylate salt is acidified with a suitable acid, for instance TFA or HC1, to afford the carboxylic acid 1-3. Alternatively, the intermediate carboxylate salt can be isolated, if desired. Scheme π
Figure imgf000011_0001
Figure imgf000011_0002
Figure imgf000011_0003
a) TFA, CH2C12; b) 1.0 N LiOH, aqueous THF.
If the amine partner contains a protecting group, the protecting group can be removed either prior or subsequently to the ester hydrolysis step, using methods suitable for selective deprotection of the specific protecting group employed. Such methods are described in Green, "Protective Groups in Organic Synthesis"
(published by Wiley-Interscience). For example, if the amine partner contains a nitrogen group which is protected by a tert-butoxycarbonyl (BOC) group, such as in compound π-1 (prepared by the general methods described above), the BOC group is removed using acidic conditions, such as TFA in CH2C12 or HC1 in dioxane, to afford the intermediate ammonium salt II-2. Subsequent ester hydrolysis followed by acidification is accomplished as described in Scheme I to afford π-3. Scheme III
Figure imgf000012_0001
Figure imgf000012_0002
Figure imgf000012_0003
a) H2, PtO2, 1.0 N HC1, MeOH; b) 1.0 N LiOH, aqueous THF
Piperidine-containing compounds, such as HI- 3, can be prepared either from a suitably N-protected piperidine derivative, according to the methods described in Schemes I and π, or from a pyridine precursor, such as HI-l. For example, the pyridine subunit of HI-l can be reduced to the corresponding piperidine group by hydrogenation over a suitable catalyst, preferably PtO2, in the presence of acid, such as HC1. The resulting piperidinium salt IH-2 is then converted to compound πi-3 by the methods described in Scheme I.
The core 6-7 fused ring system is prepared from compounds of the general formula (II):
Figure imgf000012_0004
(H) wherein R10 is NHR1, CO2H and synthetic equivalents thereof, X and X' are as defined for formula (I) and R2 and R3 are as defined in formula (I) with any reactive groups protected. Representative methods for preparing the substituted benzodiazepine nucleus are well known in the art, e.g., Hynes, et al., J. Het. Chem. , 1988, 25, 1173; Muller, et a , Helv. Chim. Acta., 1982, 65, 2118; Mori, et al, Heterocycles, 1981, 16, 1491. Similarly, methods for preparing benzazepines, 1,4- benzothiazepines, 1,4-benzoxazepines and 1,4-benzodiazepines are known and are disclosed, for instance, in Bondinell, et al, International Patent Application WO 93/00095.
Representative methods for preparing the benzodiazepine nucleus are given by Schemes IV - VI. A representative method for preparing a benzazepine nucleus is given by Scheme VII. A representative method for preparing a benzothiazepine is given by Scheme VIII. An benzoxazepine nucleus may be prepared in the same manner as Scheme VIII, except substituting a benzyl alcohol for a benzyl thiol.
Scheme IV
O N
Figure imgf000013_0001
Figure imgf000013_0002
Scheme V
Figure imgf000014_0001
Figure imgf000014_0002
Figure imgf000014_0003
Scheme VI
Figure imgf000014_0004
Figure imgf000014_0005
Figure imgf000014_0006
Scheme VJ3
1) R -NHc
Figure imgf000015_0001
2 2 2))) (( (EEBoc)20
Figure imgf000015_0002
NaOMe
Figure imgf000015_0003
Figure imgf000015_0004
NBS = N-bromosuccinimide
Scheme VHI
Figure imgf000016_0001
Figure imgf000016_0002
Figure imgf000016_0003
Figure imgf000016_0004
5 The simple tri-substituted benzene starting materials are commercially available or prepared by routine methods well known in the art.
Coupling reagents as used herein denote reagents which may be used to form peptide bonds. Typical coupling methods employ carbodiimides, activated anhydrides and esters and acyl halides. Reagents such as EDC, DCC, DPPA, BOP 10. reagent, HOBt, N-hydroxysuccinimide and oxalyl chloride are typical.
Coupling methods to form peptide bonds are generally well known to the art. The methods of peptide synthesis generally set forth by Bodansky et al, THE PRACTICE OF PEPTIDE SYNTHESIS, Springer-Verlag, Berlin, 1984, Ali et al. in J. Med. Chem., 29, 984 (1986) and J. Med. Chem., 30, 2291 (1987) are generally 15 illustrative of the technique and are incorporated herein by reference.
Typically, the amine or aniline is coupled via its free amino group to an appropriate carboxylic acid substrate using a suitable carbodiimide coupling agent, such as Ν,Ν' dicyclohexyl carbodiimide (DCC), optionally in the presence of catalysts such as 1-hydroxybenzotriazole (HOBt) and dimethylamino pyridine 20 (DMAP). Other methods, such as the formation of activated esters, anhydrides or acid halides, of the free carboxyl of a suitably protected acid substrate, and subsequent reaction with the free amine of a suitably protected amine, optionally in the presence of a base, are also suitable. For example, a protected Boc-amino acid or Cbz-amidino benzoic acid is treated in an anhydrous solvent, such as methylene chloride or tetrahydrofuran(THF), in the presence of a base, such as N-methyl morpholine, DMAP or a trialkylamine, with isobutyl chloroformate to form the "activated anhydride", which is subsequently reacted with the free amine of a second protected amino acid or aniline.
Acid addition salts of the compounds are prepared in a standard manner in a suitable solvent from the parent compound and an excess of an acid, such as hydrochloric, hydrobromic, hydrofluoric, sulfuric, phosphoric, acetic, trifluoroacetic, maleic, succinic or methanesulfonic. Certain of the compounds form inner salts or zwitterions which may be acceptable. Cationic salts are prepared by treating the parent compound with an excess of an alkaline reagent, such as a hydroxide, carbonate or alkoxide, containing the appropriate cation; or with an appropriate organic amine. Cations such as Li+, Na+, K+, Ca++, Mg++ and NH4"1" are specific examples of cations present in pharmaceutically acceptable salts.
This invention also provides a pharmaceutical composition which comprises a compound according to formula (I) and a pharmaceutically acceptable carrier. Accordingly, the compounds of formula (I) may be used in the manufacture of a medicament. Pharmaceutical compositions of the compounds of formula (I) prepared as hereinbefore described may be formulated as solutions or lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use. The liquid formulation may be a buffered, isotonic, aqueous solution. Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution. Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as polyvinylpyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate. Alternately, these compounds may be encapsulated, tableted or prepared in a emulsion or syrup for oral administration. Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition. Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin. Liquid carriers include syrup, peanut oil, olive oil, saline and water. The carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage unit. The pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms. When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension. Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule. For rectal administration, the compounds of this invention may also be combined with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository.
The compounds described herein are antagonists of the vitronectin receptor, and are useful for treating diseases wherein the underlying pathology is attributable to ligand or cell which interacts with the vitronectin receptor. For instance, these compounds are useful for the treatment of diseases wherein loss of the bone matrix creates pathology. Thus, the instant compounds are useful for the treatment of ostoeporosis, hyperparathyroidism, Paget's disease, hypercalcemia of malignancy, osteolytic lesions produced by bone metastasis, bone loss due to immobilization or sex hormone deficiency. The compounds of this invention are also believed to have utility as antitumor, antϋnflammatory, anti-angiogenic and anti-metastatic agents, and be useful in the treatment of cancer, atherosclerosis and restenosis.
The peptide is administered either orally or parenterally to the patient, in a manner such that the concentration of drug is sufficient to inhibit bone resorption, or other such indication. The pharmaceutical composition containing the peptide is administered at an oral dose of between about 0.1 to about 50 mg/kg in a manner consistent with the condition of the patient. Preferably the oral dose would be about 0.5 to about 20 mg/kg. For acute therapy, parenteral administration is preferred. An intravenous infusion of the peptide in 5% dextrose in water or normal saline, or a similar formulation with suitable excipients, is most effective, although an intramuscular bolus injection is also useful. Typically, the parenteral dose will be about 0.01 to about 100 mg/kg; preferably between 0.1 and 20 mg/kg. The compounds are administered one to four times daily at a level to achieve a total daily dose of about 0.4 to about 400 mg/kg/day. The precise level and method by which the compounds are administered is readily determined by one routinely skilled in the art by comparing the blood level of the agent to the concentration required to have a therapeutic effect. The compounds may be tested in one of several biological assays to determine the concentration of compound which is required to have a given pharmacological effect.
INHIBITION OF VITRONECTIN BINDING
Solid-Phase [3H]-SK&F-107260 Binding to ccvβ3: Human placenta or human platelet αvβ3 (0.1-0.3 mg/mL) in buffer T (containing 2 mM CaCl2 and 1% octylglucoside) was diluted with buffer T containing 1 mM CaCl2, 1 mM MnCl2, 1 mM MgCl2 (buffer A) and 0.05% NaN3, and then immediately added to 96-well ELISA plates (Corning, New York, NY) at 0.1 mL per well. 0.1 - 0.2 μg of αvβ3 was added per well. The plates were incubated overnight at 4°C. At the time of the experiment, the wells were washed once with buffer A and were incubated with 0.1 mL of 3.5% bovine serum albumin in the same buffer for 1 hr at room temperature. Following incubation the wells were aspirated completely and washed twice with 0.2 mL buffer A.
Compounds were dissolved in 100% DMSO to give a 2 mM stock solution, which was diluted with binding buffer (15 mM Tris-HCl (pH 7.4), 100 mM NaCl, 1 mM CaCl2, 1 mM MnCl2, 1 mM MgCl2) to a final compound concentration of 100 μM. This solution is then diluted to the required final compound concentration. Various concentrations of unlabeled antagonists (0.001 - 100 μM) were added to the wells in triplicates, followed by the addition of 5.0 nM of [3H]- SK&F- 107260 (65 - 86 Ci/mmol).
The plates were incubated for 1 hr at room temperature. Following incubation the wells were aspirated completely and washed once with 0.2 mL of ice cold buffer A in a well-to- well fashion. The receptors were solubilized with 0.1 mL of 1% SDS and the bound [3H]-SK&F- 107260 was determined by liquid scintillation counting with the addition of 3 mL Ready Safe in a Beckman LS Liquid Scintillation Counter, with 40% efficiency. Nonspecific binding of [3H]- SK&F- 107260 was determined in the presence of 2 μM SK&F- 107260 and was consistently less than 1% of total radioligand input. The IC50 (concentration of the antagonist to inhibit 50% binding of [3H]-SK&F- 107260) was determined by a nonlinear, least squares curve-fitting routine, which was modified from the LUNDON-2 program. The Kj (dissociation constant of the antagonist) was calculated according to the equation: Ki = IC 50/(1 + IJKd), where L and Kd were the concentration and the dissociation constant of [3H]-SK&F- 107260, respectively. Compounds of the present invention inhibit vitronectin binding to SK&F 107260 in the concentration range of 0.1 to 25 micromolar. Preferred compounds inhibit vitronectin binding at a concentration of less than 1 micromolar.
Compounds of this invention are also tested for in vitro and in vivo bone resorption in assays standard in the art for evaluating inhibition of bone formation, such as the pit formation assay disclosed in EP 528 587, which may also be performed using human osteoclasts in place of rat osteoclasts, and the ovarectomized rat model, described by Wronski et al, Cells and Materials 1991, Sup. 1, 69-74.
PARATHYROIDECTOMIZED RAT MODEL
Each experimental group consists of 5-6 male Sprague-Dawley rats. The rats are parathyroidectomized (by the vendor, Taconic Farms) 7 days prior to use. Twenty four hours prior to use, circulating ionized calcium levels are measured in whole blood immediately after it has been withdrawn by tail venipuncture into heparinized tubes. Rats are included if ionized Ca level (measured with a Ciba-Corning model 634 calcium pH analyzer) is < 1.2 mM/L. The rats are then put on a diet of calcium-free chow and deionized water. At the start of the experiment the rats weigh approximately lOOg. Baseline Ca levels are measured and the rats are administered control vehicle (saline) or compound (dissolved in saline) as a single intravenous (tail vein) bolus injection followed immediately by a single subcutaneous injection of either human parathyroid hormone 1-34 peptide (hPTHl-34, dose 0.2mg/kg in saline/0.1% bovine serum albumen, Bachem, Ca) or the PTH vehicle. The calcemic response to PTH (and any effect of compound on this response) is measured 2h after compound/PTH administration.
RAT ULNA DRIFT MODEL
Each experimental group consists of 8-10 male Sprague-Dawley or Wistar rats of approximately 30-40g body weight at the start of the experiment. The agent being tested is administered by an appropriate route as single or multiple daily doses for a period of seven days. Prior to administration of the first dose, the rats are given a single dose of a fluorescent marker (tetracycline 25mg/kg, or calcein lOmg/kg) that labels the position of bone forming surfaces at that point in time. After dosing of compound has been completed, the rats are killed and both forelimbs are removed at the elbow, the foot is removed at the ankle and the skin removed. The sample is frozen and mounted vertically on a microtome chuck. Cross sections of the midshaft region of the ulna are cut in the cryostat. The rate of bone resorption is measured morphometrically in the medial-dorsal portion of the cortical bone. The measurement is done as follows: the amount of bone resorbed at the periosteal surface is equal to the distance by which the periosteal surface has advanced towards the fluorescent label which had been incorporated at the endosteal bone formation surface on day zero; this distance is calculated by subtracting the width of bone between the label and the periosteal surface on day 7 from the width on day zero; the resorption rate in microns per day is calculated by dividing the result by 7.
HUMAN OSTEOCLAST RESORPTION ASSAY ( PIT ASSAY")
• Aliquots of osteoclastoma-derived cell suspensions are removed from liquid nitrogen strorage, warmed rapidly at 37°C and washed xl in RPMI-1640 medium by centrifugation (lOOOrpm, 5 mins at 4°C).
• Aspirate the medium and replace it with murine anti-HLA-DR antibody, diluted 1:3 in RPMI-1640 medium. Incubate for 30 mins on ice and mix the cell suspension frequently.
• The cells are washed x2 with cold RPMI-1640 by centrifugation (lOOOrpm, 5 mins at 4°C) and the cells are transferred to a sterile 15 ml centrifuge tube. The number of mononuclear cells are enumerated in an improved Neubauer counting chamber.
• Sufficient magnetic beads (5 / mononuclear cell), coated with goat anti-mouse IgG, are removed from their stock bottle and placed into 5 ml of fresh medium (this washes away the toxic azide preservative). The medium is removed by immobilizing the beads on a magnet and is replaced with fresh medium.
• The beads are mixed with the cells and the suspension is incubated for 30 mins on ice. The suspension is mixed frequently.
• The bead-coated cells are immobilized on a magnet and the remaining cells (osteoclast-rich fraction) are decanted into a sterile 50 ml centrifuge tube.
• Fresh medium is added to the bead-coated cells to dislodge any trapped osteoclasts. This wash process is repeated xlO. The bead-coated cells are discarded.
• The osteoclasts are enumerated in a counting chamber, using a large-bore disposable plastic pasteur to charge the chamber with the sample. • The cells are pelleted by centrifugation and the density of osteoclasts adjusted to 1.5xl04/ml in EMEM medium, supplemented with 10% fetal calf serum and 1.7g/litre of sodium bicarbonate.
• 3ml aliquots of the cell suspension ( per treatment) are decanted into 15ml centrifuge tubes. The cells are pelleted by centrifugation. • To each tube 3ml of the appropriate treatment are added (diluted to 50 uM in the EMEM medium). Also included are appropriate vehicle controls, a positive control (87MEM1 diluted to 100 ug/ml) and an isotype control (IgG2a diluted to 100 ug/ml). Incubate at 37°C for 30 mins.
• 0.5ml aliquots of the cells are seeded onto sterile dentine slices in a 48-well plate and incubated at 37°C for 2 hours. Each treatment is screened in quadruplicate. • The slices are washed in six changes of warm PBS (10 ml / well in a 6- well plate) and then placed into fresh treatment or control. Incubate at 37°C for 48 hours. tartrate resistant acid phosphatase (trap) procedure (selective stain for cells of the osteoclast lineage).
• The slices are washed in phosphate buffered saline and fixed in 2% gluteraldehyde (in 0.2M sodium cacodylate) for 5 mins.
• They are washed in water and incubated in TRAP buffer for 5 mins at 37°C.
• Following a wash in cold water they are incubated in cold acetate buffer / fast red garnet for 5 mins at 4°C.
• Excess buffer is aspirated, and the slices are air dried following a wash in water. • The TRAP positive osteoclasts are enumerated by bright-field microscopy and are then removed from the surface of the dentine by sonication.
• Pit volumes are determined using the Nikon/Lasertec ILM21W confocal microscope.
INHIBITION OF RGD-MEDIATED GPIIB-IIIA BINDING
Purification of GPIIb-IIIa
Ten units of outdated, washed human platelets (obtained from Red Cross) were lyzed by gentle stirring in 3% octylglucoside, 20 mM Tris-HCl, pH 7.4, 140 mM NaCl, 2 mM CaCl2 at 4°C for 2 h. The lysate was centrifuged at 100,000g for 1 h. The supernatant obtained was applied to a 5 mL lentil lectin sepharose 4B column (E.Y. Labs) preequilibrated with 20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 2 mM CaCl , 1% octylglucoside (buffer A). After 2 h incubation, the column was washed with 50 mL cold buffer A. The lectin-retained GPIIb-IIIa was eluted with buffer A containing 10% dextrose. All procedures were performed at 4°C. The GPIIb-IIIa obtained was >95% pure as shown by SDS polyacrylamide gel electrophoresis.
Incorporation of GPHb-IIIa in Liposomes.
A mixture of phosphatidylserine (70%) and phosphatidylcholine (30%) (Avanti Polar Lipids) were dried to the walls of a glass tube under a stream of nitrogen. Purified GPϋb-ϋla was diluted to a final concentration of 0.5 mg/mL and mixed with the phospholipids in a protein:phospholipid ratio of 1:3 (w:w). The mixture was resuspended and sonicated in a bath sonicator for 5 min. The mixture was then dialyzed overnight using 12,000-14,000 molecular weight cutoff dialysis tubing against a 1000-fold excess of 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 2 mM CaC12 (with 2 changes). The GPIIb-IIIa-containing liposomes wee centrifuged at 12,000g for 15 min and resuspended in the dialysis buffer at a final protein concentration of approximately 1 mg/mL. The liposomes were stored at -70C until needed.
Competitive Binding to GPIIb-IIIa The binding to the fibrinogen receptor (GPIIb-IIIa) was assayed by an indirect competitive binding method using [3H]-SK&F- 107260 as an RGD-type ligand. The binding assay was performed in a 96-well filtration plate assembly (Millipore Corporation, Bedford, MA) using 0.22 um hydrophilic durapore membranes. The wells were precoated with 0.2 mL of 10 μg/mL polylysine (Sigma Chemical Co., St. Louis, MO.) at room temperature for 1 h to block nonspecific binding. Various concentrations of unlabeled benzadiazapines were added to the wells in quadruplicate. [3H]-SK&F- 107260 was applied to each well at a final concentration of 4.5 nM, followed by the addition of 1 μg of the purified platelet GPHb-πia-containing liposomes. The mixtures were incubated for 1 h at room temperature. The GPIIb-IIIa-bound [3HJ-SK&F- 107260 was seperated from the unbound by filtration using a Millipore filtration manifold, followed by washing with ice-cold buffer (2 times, each 0.2 mL). Bound radioactivity remaining on the filters was counted in 1.5 mL Ready Solve (Beckman Instruments, Fullerton, CA) in a Beckman Liquid Scintillation Counter (Model LS6800), with 40% efficiency. Nonspecific binding was determined in the presence of 2 μM unlabeled SK&F- 107260 and was consistently less than 0.14% of the total radioactivity added to the samples. All data points are the mean of quadruplicate determinations.
Competition binding data were analyzed by a nonlinear least-squares curve fitting procedure. This method provides the IC50 of the antagonists (concentration of the antagonist which inhibits specific binding of [3H]-SK&F-107260 by 50% at equilibrium). The IC50 is related to the equilibrium dissociation constant (Ki) of the antagonist based on the Cheng and Prusoff equation: Ki = IC50/(l+L/Kd), where L is the concentration of [3H]-SK&F-107260 used in the competitive binding assay (4.5 nM), and Kd is the dissociation constant of [3HJ-SK&F-107260 which is 4.5 nM as determined by Scatchard analysis.
Preferred compounds of this invention have an affinity for the vitronectin receptor relative to the fibrinogen receptor of greater than 3:1. More preferred compounds have a ratio of activity of greater than 10:1. The comparative results of the enhanced binding of the compounds of this invention to the vitronecton receptor relative to the fibrinogen receptor are given in Table 1 below:
Figure imgf000024_0001
Figure imgf000024_0002
* enhanced binding to vitronectn receptor vs fibrinogen receptor = πbβ3/αvβ3
Figure imgf000025_0001
Figure imgf000025_0002
Vascular smooth muscle cell migration assay
The compounds of the instant invention were tested for their ability to inhibit the migration and proliferation of smooth muscle tissue in an artery or vein in order to assess their ability to prevent restenosis of an artery, such as that which typically occurs following angioplasty.
Rat or human aortic smooth muscle cells were used. The cell migration was monitored in a Transwell cell culture chamber by using a polycarbonate membrane with pores of 8 urn (Costar). The lower surface of the filter was coated with vitronectin. Cells were suspended in DMEM supplemented with 0.2% bovine serum albumin at a concentration of 2.5 - 5.0 x 106 cells/mL, and were pretreated with test compound at various concentrations for 20 min at 20°C. The solvent alone was used as control. 0.2 mL of the cell suspension was placed in the upper compartment of the chamber. The lower compartment contained 0.6 mL of DMEM supplemented with 0.2% bovine serum albumin. Incubation was carried out at 37 °C in an atmosphere of 95% air/5% CO2 for 24 hr. After incubation, the non- migrated cells on the upper surface of the filter were removed by gentle scraping. The filter was then fixed in methanol and stained with 10% Giemsa stain. Migration was measured either by a) counting the number of cells that had migrated to the lower surface of the filter or by b) extracting the stained cells with 10% acetic acid followed by determining the absorbance at 600 nM.
Examples
Nuclear magnetic resonance spectra were recorded at either 250 or 400 MHz using, respectively, a Bruker AM 250 or Bruker AC 400 spectrometer. CDCI3 is deuteriochloroform, DMSO-dό is hexadeuteriodimethylsulfoxide, and CD3OD is tetradeuteriomethanol. Chemical shifts are reported in parts per million (5) downfield from the internal standard tetramethylsilane. Abbreviations for NMR data are as follows: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, dd=doublet of doublets, dt=doublet of triplets, app=apparent, br=broad. J indicates the NMR coupling constant measured in Hertz. Infrared (IR) spectra were recorded on a Perkin-Elmer 683 infrared spectrometer in transmission mode. IR band positions are reported in inverse wavenumbers (cm-1). Mass spectra were taken on either VG 70 FE, PE Syx API III, or VG ZAB HF instruments, using fast atom bombardment (FAB) or electrospray (ES) ionization techniques. Elemental analyses were obtained using a Perkin-Elmer 240C elemental analyzer. Melting points were taken on a Thomas-Hoover melting point apparatus and are uncorrected. All temperatures are reported in degrees Celsius.
Analtech Silica Gel GF and E. Merck Silica Gel 60 F-254 thin layer plates were used for thin layer chromatography. Both flash and gravity chromatography were carried out on E. Merck Kieselgel 60 (230-400 mesh) silica gel. Analytical and preparative HPLC were carried out on Rainin or Beckman chromatographs. ODS refers to an octadecylsilyl derivatized silica gel chromatographic support. 5 μ Apex-ODS indicates an octadecylsilyl derivatized silica gel chromatographic support having a nominal particle size of 5 μ, made by Jones Chromatography, Littleton, Colorado. YMC ODS-AQ® is an ODS chromatographic support and is a registered trademark of YMC Co. Ltd., Kyoto, Japan. PRP-1® is a polymeric (styrene-divinylbenzene) chromatographic support, and is a registered trademark of Hamilton Co., Reno, Nevada. Celite® is a filter aid composed of acid-washed diatomaceous silica, and is a registered trademark of Manville Corp., Denver, Colorado.
Methyl (±)-7-carboxy-3-oxo-2-(2-phenylethyl)-2,3,4,5-tetrahydro- 1H-1 ,4- benzodiazepine-2-acetate, methyl (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5- tetrahydro-lH-l,4-benzodiazepine-2-acetate, and 3-amino-(N- benzyloxycarbonyl)benzamidine were prepared by the method of Bondinell, et al., WO 93/00095. Methyl (±)-8-carboxy-2-methyl-3-oxo-2,3,4,5-tetrahaydro-lH-2- benzazepine-4-acetate was prepared by the method disclosed in Example 1 of WO 94/14776, except substituting 4-bromo-3-methylbenzoic acid for 3-bromo-4- methylbenzoic acid and substituting methylamine for phenethylamine therein. 4-(2-Methylpyridyl) piperazine was prepared by the procedure of Cross and Dickinson, US 4,806,536 (Feb. 21, 1989).
Example 1
Preparation of (+V7-r[(6-Amino-2-pyridinyl.aminolcarbonyll-4-methyl-3-oxo- 2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid
a) Methyl (±)-7-[[(6-amino-2-pyridinyl)amino]carbonyl]-4-methyl-3-oxo-2,3,4,5- tetrahydro- 1 H- 1 ,4-benzodiazepine-2-acetate Diisopropylethylamine (0.29 g, 2.25 mmol) was added in one portion to a stirred mixture of 2,6-diaminopyridine (0.2 g, 1.8 mmol), methyl (±)-7-carboxy-4- methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (0.44 g, 1.50 mmol), EDC (0.34 g, 1.8 mmol) and HOBT H2O (0.24 g, 1.8 mmol) in DMF (8 mL) at RT under argon. After 24 h, the brownish solution was poured into a mixture of ice-water (90 g) and 5% NaHCO3 (10 mL). The resulting precipitate was filtered and air-dried to give an off-white solid (0.53 g). Flash chromatography (silica gel, 7% MeOH CH2Cl2) yielded the title compound (0.04 g, 7%): 1H NMR (250 MHz, CDCI3) δ 6.26-8.20 (m, 6H), 5.47 (d, J=16 Hz, 1H), 5.12 (dd, J=l 1, 6 Hz, 1H), 4.59 (d, J=4 Hz, 2H), 3.80 (d, J=16 Hz, 1H), 3.76 (s, 3H), 3.09 (s, 3H), 3.00 (dd, J=16, 6 Hz, 1H), 2.68 (dd, J=16, 6 Hz, 1H); MS (ES) m/e 384.2 (M+H)+.
b) (±)-7-[[(6-Amino-2-pyridinyl)amino]carbonyl]-4-methyl-3-oxo-2,3,4,5- tetrahydro- 1H- 1 ,4-benzodiazepine-2-acetic acid
1.0 N LiOH (0.26 mL, 0.26 mmol) was added dropwise in RT to a mixture of methyl (±)-7-[[(6-amino-2-pyridinyl)amino]carbonyl]-4-methyl-3-oxo-2,3,4,5- te_rahydro-lH-l,4-benzodiazepine-2-acetate (0.044 g, 0.12 mmol) in THF (4 mL) and H2O (5 mL). The resulting light yellowish-brown solution was stirred for 23 h, then was concentrated on the rotavap. The resulting residue was lyophilized to give the crude product as a yellowish powder (0.051 g). Preparative HPLC (PRP-1® column, step gradient, 10-15% CH3CN/H2O-0.1 % TFA) afforded the title compound: !H NMR (250 MHz, DMSO-d6) δ 10.75 (br, 1H), 6.46-8.29 (m, 6H), 5.73 (s, 1H), 5.53 (d, J=17 Hz, 1H), 5.17 (br, 1H), 3.88 (d, J=17 Hz, 1H), 2.96 (s, 3H), 2.83 (dd, J=17, 9 Hz, 1H), 2.58 (dd, J=17, 5 Hz, 1H); MS (ES) m e 370.2 (M+H)+. Anal. Calcd for C18H19N5O4 • 9/4 CF3CO2H • 1/2 H2O: C, 42.56; H, 3.53; N, 11.03. Found: C, 42.20; H, 3.02; N, 11.36.
Example 2
Preparation of .±y8-[lf6-amino-2-pyridinyl.aminolcarbonyl .-2-methyl-3-oxo- 2.3.4.5-tetrahydro-lH-2-benzazepine-4-acetic acid
a) Methyl (±)-8-[[(6-amino-2-pyridinyl)amino]carbonyl]-2-methyl-3-oxo-2,3,4,5- tetrahydro- 1 H-2-benzazepine-4-acetate
A mixture of methyl (+)-8-carboxy-2-methyl-3-oxo-2,3,4,5-tetrahaydro-lH- 2-benzazepine-4-acetate (300 mg, 1.03 mmol) and thionyl chloride (10 mL) was refluxed for 1 h. The resulting solution was concentrated to dryness to yield a foam. This was dissolved in CH2CI2 (10 mL) and added dropwise to a solution of 2.6-diaminopyridine (0.34 g, 3.09 mmol) in CH2CI2 (10 mL) and DMF (3 mL) at RT under argon. After 110 min, the reaction mixture was partitioned between CH2CI2 (150 mL) and 5% NaHCO3 (70 mL). The organic layer was separated, washed sequentially with 5% NaHCO3 (50 mL) and H2O (50 mL), dried (Na2SO4), and concentrated to leave a yellowish solid (0.69 g). Recrystallization from MeOH/CH2Cl2/EtOAc afforded the title compound (0.16 g, 41%): 1H NMR (250 MHz, CDCl3/DMSO-d6) δ 6.63-10.00 (m, 6H), 5.71 (s, 2H), 5.30 (d, J=16 Hz, IH), 4.07 (d, J=17 Hz, IH), 3.83 (m, IH), 3.61 (s, 3H), 2.93 (s, 3H), 2.71-3.25 (m, 3H), 2.45 (dd, J=17, 5 Hz, IH); MS (ES) m/e 383.2 (M+H)+.
b) (±)-8-[[(6-Amino-2-pyridinyl)amino]carbonyl]-2-methyl-3-oxo-2,3,4,5- te_rahydro-lH-2-benzazepine-4-acetic acid
1.0 N LiOH (0.92 mL, 0.92 mmol) was added dropwise at RT to a mixture of the compound of Example 2(a) (160 mg, 0.42 mmol) in THF (6.5 mL) and H2O (8 mL). The resulting solution was stirred for 21.5 h, then concentrated on the rotavap. The resulting residue was lyophilized to give the crude product, and purified by preparative HPLC (PRP- 1 ® column, step gradient, 10-20%
CH3CN/H2O-0.1% TFA) to yield the title compound: 1H NMR (250 MHz, DMSO-d6) δ 11.13 (br, IH), 6.52-7.88 (m, 6H), 5.35 (d, J=16 Hz, IH), 4.10 (d, J=17 Hz, IH), 3.82 (m, IH), 2.94 (s, 3H), 2.53-3.22 (m, 3H), 2.37 (dd, J=17, 5 Hz, IH); MS (ES) m/e 369.2 (M+H)+. Anal. Calcd for Ci9H2oN4O4 • 3/2 CF3CO2H: C, 48.99; H, 4.02; N, 10.39. Found: C, 48.75; H, 4.23; N, 10.35.
Example 3
Preparation of .±V7-ll(6-amino-3-pyridinyl.aminolcarbonyll-3-oxo-4-(2- phenylethyl. -2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid
a) Methyl (±)-7-[[(6-amino-3-pyridinyl)amino]carbonyl]-3-oxo-4-(2-phenylethyl)- 2,3,4,5-tetrahydro-lH- 1 ,4-benzodiazepine-2-acetate
Following the procedure of Example 1(a), substituting methyl (±)-7- c__rboxy-3-oxo-2-(2-phenylethyl)-2,3,4,5-tetr_-hydro-lH-l,4-benzodiazepine-2- acetate for methyl (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4- benzodiazepine-2-acetate, and substituting 2,5-diaminopyridine for 2,6- diaminopyridine, the title compound was prepared (0.42 g, 42%): 1H NMR (250 MHz, CDCl3/DMSO-d6) δ 6.14-9.46 (m, 7H), 5.35-5.44 (br, 3H), 5.13 (m, IH), 3.68 (s, 3H), 3.55-3.83 (m, 3H), 2.94 (dd, J=17, 8 Hz, IH), 2.78 (t, 2H), 2.66 (dd, J=17, 5 Hz, IH); MS (ES) m e 474.2 (M+H)+.
b) (±)-7-[[(6-Amino-3-pyridinyl)amino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5- tetrahydro- IH- 1 ,4-benzodiazepine-2-acetic acid 1.0 N LiOH (1.1 mL, 1.1 mmol) was added dropwise to a mixture of methyl
(±)-7-[[(6-amino-3-pyridinyl)amino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5- tetrahydro-lH-l,4-benzodiazepine-2-acetate (0.23 g, 0.48 mmol) in THF (12 mL) and H2O (17 mL) at RT. After 22.5 h, the dark reddish-brown reaction mixture was concentrated on the rotavap to remove excess THF. The resulting reddish solution was cooled in an ice-bath, and neutralized with 1.0 N AcOH (1.8 mL). The precipitate was collected by suction filtration, washed with water and ether, and air-dried to give the title compound (0.19 g, 86%) as a pinkish-purple solid: 1H NMR (400 MHz, DMSO-d6) δ 9.55 (s, IH), 6.40-8.29 (m, 7H), 5.69 (s, 2H), 5.42 (d, J=17 Hz, IH), 5.09 (br, IH), 3.95 (dd, J=17,1H), 3.59-3.65 (m, 2H), 2.51- 2.82 (m, 4H); MS (ES) m/e 460.2 (M+H)+. Anal. Calcd for C25H25N5O4 • 9/4 H2O: C, 60.05; H, 5.98; N, 14.01. Found: C, 59.79; H, 5.92; N, 13.64.
Example 4
Preparation of ■±)-l-Acetyl-7-. r(6-amino-2-pyridinyl.amino1carbonyll-4-methyl-3- oxo-2.3.4.5-tetrahvdro- 1 H- 1 ,4-benzodiazepine-2-acetic acid
a) Methyl (±)-l-acetyl-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4- benzodiazepine-2-acetate
Methyl (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4- benzodiazepine-2-acetate (2.0 g, 8.6 mmol), acetic anhydride (25 mL) and acetic acid (1 mL) were heated to reflux. After 48 h, the reaction was concentrated, and the residue was diluted with H2O (20 mL) and MeOH (15 mL). The resulting solution was concentrated to give the title compound (1.8 g, 78%): ^H NMR (400 MHz, DMSO-d6) δ 1.7-1.8 (s, 3H), 2.2-2.6 (m, 2H), 2.9-3.0 (s, 3H), 3.5-3.6 (s, 3H), 4.2-4.3 (d, IH), 4.7-4.8 (d, IH), 5.8-5.9 (t, IH), 7.5-7.6 (d, IH), 7.9-8.0 (dd, IH), 8.1-8.2 (d, IH); MS (ES) m/e 335.0 (M+H)+.
b) Methyl (±)- 1 -acetyl-7-[[(6-amino-2-pyridinyl)amino]carbonyl]-4-methyl-3-oxo- 2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate
HOBT • H2O (0.54 g, 3.6 mmol) and EDC (0.686 g, 3.6 mmol) were added to a solution of methyl (±)-l-acetyl-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro- lH-l,4-benzodiazepine-2-acetate (1.0 g, 3 mmol) in dry DMF (15 mL). After 1 h the reaction solution was added dropwise to a solution of 2,6-diaminopyridine (0.326 g, 3.0 mmol) in dry DMF (20 mL). The reaction solution was stirred for 18 h, then was concentrated. Chromatography (silica gel, 9:1 CH2θ2/MeOH) gave the title compound (0.9 g, 70%): 1H NMR (400 MHz, DMSO-d6) δ 1.80 (s, 3H), 2.3-2.7 (m, 2H), 3.0-3.1 (s, 3H), 3.5-3.6 (s, 3H), 4.1-4.2 (d, IH), 4.7-4.8 (d, IH), 5.7-5.9 (m, 3H), 6.2-6.3 (d, IH), 7.3-7.5 (m, 3H), 8.0-8.1 (d, IH), 8.2-8.3 (s, IH); MS (ES) m/e 426.0 (M+H)+.
c) (±)-l-Acetyl-7-[[(6-amino-2-pyridinyl)amino]carbonyl]-4-methyl-3-oxo- 2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid
1 N NaOH (1.0 mL, 1.0 mmol) was added to a cold solution of methyl (±)- l-acetyl-7-[[(6-amino-2-pyridinyl)amino]carbonyl]-4-methyl-3-oxo-2,3,4,5- tetrahydro-lH-l,4-benzodiazepine-2-acetate (0.23 g, 0.54 mmol), MeOH (2 mL) and H O (1 mL). The solution was stirred at room temperature for 18 h then was concentrated. Chromatography (ODS, 10% CH3CN/H2O-0.1% TFA) gave the title compound (0.215 g, 90%): 1H NMR (400 MHz, DMSO-d6) δ 1.7-1.9 (s, 3H), 2.0- 2.6 (m, 2H), 3.0-3.1 (s, 3H), 4.1-4.2 (d, IH), 4.7-4.8 (d, IH), 5.7-5.9 (m, IH), 6.4- 6.5 (d, IH), 7.0-7.1 (d, IH), 7.5-7.6 (d, IH), 7.6-7.8 (t, IH), 8.0-8.1 (d, IH), 8.2-8.3 (s, IH); MS (ES) m/e 412.2 (M+H)+. Anal. Calcd for C2oH2ιN5O5 • 2.75 CF3CO2H: C, 42.25; H, 3.30; N, 9.66. Found: C, 42.01 ; H, 3.25; N, 9.85.
Example 5
Preparation of .±.-2-methyI-3-oxo-8-rr2-(pyridinyl carbonyl1aminol-2.3.4.5- tetrahvdro- 1 H-2-benzazepine-4-acetic acid
a) Methyl (±)-8-amino-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine-4- acetate
A mixture of methyl (±)-8-[(benzyloxycarbonyl)amino]-2-methyl-3-oxo- 2,3,4,5-tetr__hydro-lH-2-benzazepine-4-acetate (1.5 g), Pearlman's catalyst (0.30 g), and warm AcOH (300 mL) was stirred under H2 (balloon pressure). After 90 min, the mixture was filtered to remove the catalyst, and the filtrate was concentrated to give the title compound as a viscous oil (1 g, 100%): l NMR (CDC13) δ 7.00 (br s, 2H), 6.88 (d, J=8.1 Hz, IH), 6.57 (dd, J=8.1, 2.3 Hz, IH), 6.43 (d, J=2.3 Hz, IH), 5.25 (d, J=16.3 Hz, IH), 3.78 (m, IH), 3.70 (s, 3H), 3.68 (d, J=16.3 Hz, IH), 3.03 (s, 3H), 3.00-2.80 (m, 3H), 2.40 (dd, J=16.7, 5.3 Hz, IH).
b) Methyl (±)-2-methyl-3-oxo-8-[[2-(pyridinyl)carbonyl]amino]-2,3,4,5- tetrahydro-lH-2-benzazepine-4-acetate To a solution stirred under argon at room temperature of methyl (±)-8- carboxy-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetate (0.30 g, 1 mmole), picolinic acid (1.2 mmole), HOBT • H2O (0.17 g, 1.2 mmole), diisopropylethylamine (0.53 g, 4 mmole), and DMF (5 mL) was added EDC (0.24 g, 1.2 mmole). The resulting mixture was stirred for 18 h, then was concentrated to dryness, and the residue was partitioned between EtOAc and H2O. The organic phase was washed with H2O and brine, dried (MgSO4), and concentrated. Purification by chromatography (silica gel, 1-5% MeOH CH2Cl2) gave the title compound as an amorphous solid (26%): JH NMR (CDCI3) δ 10.02 (s, IH), 8.62 (d, J=4.1 Hz, IH), 8.29 (d, J=7.8 Hz, IH), 7.93 (m, IH), 7.79 (d, J=2.1 Hz, IH), 7.50 (m, 2H), 7.11 (d, J=8.3 Hz, IH), 5.33 (d, J=16.6 Hz, IH), 3.88 (d, J=16.6 Hz, IH), 3.85 (m, IH), 3,72 (s, 3H), 3.06 (s, 3H), 3.00-2.85 (m, 3H), 2.43 (dd, J=16.7, 5.4 Hz, IH).
c) (±)-2-Methyl-3-oxo-8-[[2-(pyridinyl)carbonyl]amino]-2,3,4,5-tetrahydro-lH-2- benzazepine-4-acetic acid
A solution of methyl (±)-8-amino-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2- benzazepine-4-acetate (0.054 g), LiOH • H2O (0.008 g), THF (2 mL), and H2O (2 mL) was stirred at RT. After 18 h, the reaction was concentrated to dryness and the residue was dissolved in H2O. The solution was brought to pH 5 with 3N HC1, and the resulting precipitate was collected by filtration. Drying under vacuum gave the title compound as a colorless solid (0.04 g, 77%): *H NMR (DMSO-d6) δ 8.77 (d, J=4 Hz, IH), 8.24 (d, J=8 Hz, IH), 8.10 (m, IH), 7.88 (d, J=2 Hz, IH), 7.80-7.70 (m, 2H), 7.15 (d, J=8 Hz, IH), 5.35 (d, J=16 Hz, IH), 4.00 (d, J=16 Hz, IH), 3.82 (m IH), 2.97 (s, 3H), 2.78 (m, 2H), 2.55 (m, IH), 2.38 (dd, J=16, 5 Hz, 2H); MS (ES) m/e354 (M+H)+. Anal. Calcd for C19H19N3O4. 0.125 H2O: C, 64.17; H, 5.46; N, 11.82. Found: C, 63.99; H, 5.39; N, 11.77.
Example 6
Preparation of .±V8-r.benzyloxycarbonyl aminol-2-methyl-3-oxo-2.3.4.5- tetrahvdro- 1 H-2-benzazepine-4-acetic acid
a) Methyl (±)-8-[(benzyloxycarbonyl)amino]-2-methyl-3-oxo-2,3,4,5-tetrahydro- lH-2-benzazepine-4-acetate
To a solution stirred under argon at room temperature of methyl (±)-8- carboxy-2-methyl-3-oxo-2,3,4,5-tetrahydro-2-benzazepine-4-acetate (0.30 g, 1 mmol) and triethylamine (0.16 mL, 1.2 mmol) in toluene was added diphenylphosphorylazide (0.31 g, 1.2 mmol). The resulting mixture was heated at 80°C for 1 h, then was allowed to cool, and benzyl alcohol (0.22 g, 2 mmol) was added. The mixture was heated at 80°C for 4 h, then was concentrated to remove the toluene. The residue was dissolved in EtOAc, and the solution was washed sequentially with 5% aqueous NaHCO3, IN HC1, and brine. Drying (MgSO4), concentration, and chromatography (silica gel, 1% MeOH/CH Cl2) gave the title compound as a colorless solid (0.20 g, 47%): 1H NMR (CDC13) δ 7.40-7.30 (m, 6H), 7.06 (dd, J=8.3, 2 Hz, IH), 7.02 (d, J=8.3 Hz, IH), 6.65 (br s, IH), 5.28 (d, J=16.7 Hz, IH), 5.20 (s, 2H), 3.80 (m, IH), 3.79 (d, J=16.7 Hz, IH), 3.70 (s, 3H), 3.03 (s, 3H), 3.00 (m, 2H), 2.88 (m, IH), 2.41 (dd, J=16.8, 5.3, IH).
b) (±)-8-[(Benzyloxycarbonyl)amino]-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2- benzazepine-4-acetic acid
A solution of the compound of Example 6(a) (0.24 mmol), LiOH • H2O (0.013 g, 0.31 mmole), THF (2 mL), and H2O (2 mL) was stirred at RT for 18 h, then was concentrated to dryness. The residue was dissolved in H2O, and the solution was brought to pH 4-5 with 3N HC1. The resulting precipitate was collected by filtration and dried to yield the title compound (83%): lH NMR (Acetone-d6) δ 8.50 (br s, IH), 7.45 (br s, IH), 7.40-7.30 (m, 5H), 7.05 (d, J=8.3 Hz, IH), 5.31 (d, J=16.4 Hz, IH), 5.17 (s, 2H), 3.90 (d, J=16.5 Hz, IH), 3.84 (m, IH), 3.08 (dd, J=11.6, 4.9 Hz, IH); MS (ES) m/e 383.2 (M+H)+. Anal. Calcd for C2ιH22N2O5 • 0.25 H2O: C, 65.19; H, 5.86; N, 7.24. Found: C, 65.45; H, 5.90; N, 7.27.
Example 7
Preparation of (±V7-r. r3-(aminoiminomethyl)phenyllaminolcarbonyl1-4-methyl-3- oxo-2.3.4.5-tetrahydro- IH- 1.4-benzodiazepine-2-acetic acid
a) Methyl {±)-7-[[[3-[N-(benzyloxycarbonyl)aminoiminomethyl]phenyl]amino] carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid Following the procedure of Example 2(a), methyl (±)-7-carboxy-4-methyl-
3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate was converted to the corresponding acid chloride. This was dissolved in CH2CI2 (10 mL) and added dropwise to a solution of 3-amino-(N-benzyloxycarbonyl)benzamidine (1.48 g, 5.46 mmol) and pyridine (0.72 g, 9.1 mmol) in CH2CI2 (15 mL) at 0°C under argon. The mixture was stirred in RT for 2 h, then was partitioned between
CH2CI2, EtOAc and 5% NaHCO3. The organic layer was separated and washed with 0.05 N HC1, which gave a precipitate. This was collected and recrystallized from MeOH/CH2Cl2/EtOAc to afford the title compound (0.5 g, 51%): 1H NMR (400 MHz, CDCl3/DMSO-d6) δ 6.64-10.63 (m, 12H), 5.55 (d, J=16 Hz, IH), 5.38 (s, 2H), 5.19 (m, IH), 3.86 (d, J=17 Hz, IH), 3.61 (s, 3H), 3.02 (s, 3H), 2.93 (dd, J=17, 9 Hz, IH), 2.66 (dd, J=17, 4 Hz, IH).
b) Methyl £±)-7-[[[3-(aminoiminomethyl)phenyl]amino] carbonyl]-4-methyl-3- oxo-2,3,4,5-tetrahydro- IH- 1 ,4-benzodiazepine-2-acetic acid
A mixture containing the compound of Example 7(a), 10% Pd/C (0.19 g), and MeOH (30 mL) was hydrogenated at 45 psi in a Parr apparatus. After 2 h, glacial AcOH (5 mL) and more 10% Pd/C (0.15 g) were added, and hydrogenation at 45 psi was continued for an additional 70 min. The reaction mixture was filtered through a bed of Celite® and concentrated to give the title compound (0.21 g, 81%) as a white solid: !H NMR (250 MHz, DMSO-dό) δ 6.55-10.19 (m, 10H), 5.55 (d, J=16 Hz, IH), 5.18 (m, IH), 3.90 (d, J=17 Hz, IH), 3.62 (s, 3H), 2.97 (s, 3H), 2.86 (dd, J=17, 9 Hz, IH), 2.67 (dd, J=17, 5 Hz, IH); MS (ES) m/e 410.2 (M+H)+.
c) (±)-7-[[[3-(Aminoiminomethyl)phenyl]amino]carbonyl]-4-methyl-3-oxo- 2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetic acid
Following the procedure of Example 2(b), the compound of Example 7(b) was saponified and purified to give the title compound: *H NMR (250 MHz, DMSO-d6) δ 6.51-9.30 (m, 10H), 5.54 (d, J=17 Hz, IH), 5.14 (m, IH), 3.88 (d, J=17 Hz, IH), 2.98 (s, 3H), 2.82 (dd, J=17, 9 Hz, IH), 2.57 (dd, J=17, 5 Hz, IH); MS (ES) m/e 396.2 (M+H)+. Anal. Calcd for C20H2ιN5O4 • 3/2 CF3CO2H: C, 48.77; H, 4.00; N, 12.36. Found: C, 48.77; H, 4.38; N, 12.52.
Example 8
Preparation of (+V7-[rr3-(aminocarbonyl phenyllaminolcarbonyll-4-methyl-3-oxo- 2.3.4.5-tetrahvdro-lH- 1.4-benzodiazepine-2-acetic acid The title compound was isolated as a minor product from the reaction described in Example 7(c): 1H NMR (250 MHz, DMSO-d6) δ 9.91 (s, IH), 6.42- 8.25 (m, 9H), 5.53 (d, J=17 Hz, IH), 5.12 (m, IH), 3.87 (d, J=17 Hz, IH), 2.98 (s, 3H), 2.82 (dd, J=17, 9 Hz, IH), 2.57 (dd, J=17, 5 Hz, IH); MS (ES) m/e 397.0 (M+H)+. Anal. Calcd for C oH2oN5O5 • 1/3 CF3CO2H • 2/3 H20: C, 55.60; H, 4.89; N, 12.55. Found: C, 55.38; H, 5.05; N, 12.42. Example 9
Preparation of .±.-4-methyl-3-oxo-7-. l-.4-phenylpiperazinyl,carbonyri-2.3.4.5- tetrahvdro-lH-1 ,4-benzodiazepine-2-acetic acid
a) Methyl (±)-4-methyl-3-oxo-7-[l-(4-phenylpiperazinyl)carbonyl]-2,3,4,5- tetrahydro- IH- 1 ,4-benzodiazepine-2-acetate
EDC (137.6 mg, 0.72 mmol) was added to a solution of methyl (±)-7- carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (175.4 mg, 0.6 mmol), 4-phenylpiperazine (0.11 mL, 0.72 mmol), HOBT H2O (97.3 mg, 0.72 mmol), and dϋsopropylethylamine (0.21 mL, 1.2 mmol) in anhydrous DMF (3 mL) at RT. After 18 h, the reaction was concentrated on the rotavap (high vacuum), and the residue was diluted with H2O. CHC13 extraction drying (Na2SO4), concentration, and reconcentration from xylenes left a yellow oil, which solidified on treatment with EtOAc followed by concentration.
Chromatography (silica gel, 5% MeOH/CHCl3) gave an oil which was treated with EtOAc to afford a solid. Trituration with cold Et2O (2 x 20 mL) gave the title compound as an off-white solid (238.8 mg, 91%): TLC Rf (5% MeOH/CHC.3) 0.33; lH NMR (250 MHz, CDCI3) δ 7.07-7.36 (m, 4H), 6.82-7.00 (m, 3H), 6.49- 6.59 (m, IH), 5.45 (d, J=16.5 Hz, IH), 5.19 (app t, IH), 3.55-3.95 (m, 5H), 3.75 (s, 3H), 3.15-3.35 (m, 4H), 3.09 (s, 3H), 3.00 (dd, J=16.0, 6.6 Hz, IH), 2.67 (dd, J=16.0, 6.5 Hz, IH); MS (ES) m e 437.2 (M+H)+, 275.0.
b) (±)-4-Methyl-3-oxo-7-[l-(4-phenylpiperazinyl)carbonyl]-2,3,4,5-tetrahydro-lH- 1 ,4-benzodiazepine-2-acetic acid
A mixture of methyl (±)-4-methyl-3-oxo-7-[l-(4- phenylpiperazinyl)carbonyl]-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (238.8 mg, 0.55 mmol), 1.0 N NaOH (1.7 mL, 1.7 mmol), and MeOH (5.5 mL) was stirred at 35°C overnight. The resulting homogeneous solution was concentrated to dryness, and the residue was dissolved in 1:1 H2O/CH3CN. The solution was cooled to 0°C and acidified with TFA, then was concentrated to a pinkish-orange oil. Chromatography (ODS, 25% CH3CN/H O-0.1 % TFA), concentration, and lyophilization gave the title compound (213.1 mg, 69%) as an off-white powder: HPLC k' 2.6 (PRP-1®, 25% CH3CN/H2O-0.1 % TFA); *H NMR (400 MHz, CD3OD) δ 7.29-7.40 (m, 2H), 7.12-7.22 (m, 4H), 7.04 (t, J=7.4 Hz, IH), 6.63 (d, J=9.1 Hz, IH), 5.58 (d, J=16.5 Hz, IH), 5.20 (dd, J=9.0, 5.1 Hz, IH), 3.78-3.95 (m, 5H), 3.23-3.39 (m, 4 H, partially obscured by residual solvent signal), 3.04 (s, 3H), 2.94 (dd, J=16.8, 9.0 Hz, IH), 2.65 (dd, J=16.8, 5.1 Hz, IH); MS (ES) m/e 423.2 (M+H)+, 261.0. Anal. Calcd for C23H26N4O4 • 1.25 CF3CO2H: C, 54.20: H, 4.86; N, 9.92. Found: C, 54.42; H, 4.98; N, 10.00.
Example 10
Preparation of (±V4-methyl-3-oxo-7-r( 1 -piperazinyl .carbonyll-2.3.4.5-tetrahvdro- 1 H- 1.4-benzodiazepine-2-acetic acid
a) Methyl (±)-4-methyl-3-oxo-7-[l-[4-(tert-butoxycarbonyl)piperazinyl]carbonyl]- 2,3,4,5-tetrahydro- IH- 1 ,4-benzodiazepine-2-acetate
EDC (137.6 mg, 0.72 mmol) was added to a solution of methyl (±)-7- carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (175.4 mg, 0.6 mmol), 4-(tert-butoxycarbonyl)piperazine (0.21 g, 1.2 mmol), HOBT H2O (97.3 mg, 0.72 mmol), and diisopropylethylamine (0.21 mL, 1.2 mmol) in anhydrous DMF (3 mL) at RT. After 17 h, the reaction was concentrated on the rotavap (high vacuum), and the residue was partitioned between 10% Na2CO3 and CH2C12. The layers were separated and the aqueous layer was extracted with CH2C12. Drying (Na2SO4) and concentration left a residue which was reconcentrated from xylenes to remove DMF. Chromatography (silica gel, 10% MeOH in 1:1 EtOAc/CHCl3) gave the title compound as a colorless foam (266 mg, 96%): TLC R 0.54 (10% MeOH in 1:1 EtOAc/CHCl ); lU NMR (250 MHz, CDC1 ) δ 7.09-7.16 (m, 2H), 6.53 (d, J=8.9 Hz, IH), 5.44 (d, J=16.5 Hz, IH), 5.07 (t, J=6.6 Hz, IH), 3.75 (s, 3H), 3.73 (d, J=16.5 Hz, 1 H, partially obscured by the δ 3.75 resonance), 3.32-3.68 (m, 8H), 3.08 (s, 3H), 2.99 (dd,
J=16.0, 6.7 Hz, IH), 2.67 (dd, J=16.0, 6.4 Hz, IH), 1.47 (s, 9H); IR (CHC13) 3240- 3560 (br), 1729, 1685 (shoulder), 1665, 1610, 1455, 1437, 1420, 1410, 1367, 1288, 1263, 1245, 1168, 1123 cm"1; MS (ES) m/e 461.2 (M+H)+, 405.2 (M+H-C4H8)+.
b (±)-4-Methyl-3-oxo-7-[(l-piperazinyl)carbonyl]-2,3,4,5-tetrahydro-lH-l,4- benzodiazepine-2-acetic acid
TFA (2.9 mL) was added all at once to a solution of methyl (±)-4-methyl-3- oxo-7-[l-[4-(tert-butoxycarbonyl)piperazinyl]carbonyl]-2,3,4,5-tetrahydro-lH-l,4- benzodiazepine-2-acetate (266.2 mg, 0.58 mmol) in anhydrous CH2C12 (2.9 mL) at 0°C, and the reaction was warmed to RT. After 2 h, the reaction was concentrated and the residue was reconcentrated several times from 1:1 toluene/MeOH to remove residual TFA. The resulting yellow oil was dissolved in MeOH (5.8 mL) and cooled to 0°C. 1.0 N NaOH (2.9 mL, 2.9 mmol) was added, and the bright yellow solution was stirred at RT. After 20 h, the reaction was concentrated and the residue was dissolved in H2O (5 mL). The solution was acidified with TFA and concentrated to leave a light yellow oil. Chromatography (ODS, 5% CH3CN/H2O- 0.1% TFA), concentration, and lyophilization gave the title compound as a light yellow powder (206.1 mg, 66%): HPLC k' 2.2 (PRP-1®, 7% CH3CN/H2O-0.1% TFA); 1H NMR (400 MHz, CD3OD) δ 7.15-7.23 (m, 2H), 6.59-6.65 (m, IH), 5.58 (d, J=16.5 Hz, IH), 5.20 (dd, J=9.0, 5.1 Hz, IH), 3.81-3.95 (m, 5H), 3.22-3.30 (m, 4H), 3.04 (s, 3H), 2.94 (dd, J=16.7, 9.0 Hz, IH), 2.65 (dd, J=16.7, 5.1 Hz, IH); MS (ES) m/e 347.2 (M+H)+, 261.0. Anal. Calcd for Cι7H2 N4O4 • 1.5 CF3CO2H • H2O: C, 44.86: H, 4.80; N, 10.46. Found: C, 44.82; H, 4.82; N, 10.36.
Example 11
Preparation of (±V4-methyl-3-oxo-7-ri-r4-(l-piperidinv piperidinvncarbonyll- 2.3.4.5-tetrahydro-lH-1.4-benzodiazepine-2-acetic acid
a) Methyl (±)-4-methyl-3-oxo-7-[l-[4-(l-piperidinyl)piperidinyl]carbonyl]-2,3,4,5- tetrahydro- 1 H- 1 ,4-benzodiazepine-2-acetate EDC (138 mg, 0.72 mmol) was added to a solution of methyl (±)-7- carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (175 mg, 0.6 mmol), 4-(l-piperidinyl)piperidine (121.2 mg, 0.72 mmol), HOBT H2O (97 mg, 0.72 mmol), and diisopropylethylamine (0.21 mL, 1.2 mmol) in anhydrous DMF (3 mL) at RT. After 21 h, the reaction was concentrated on the rotavap (high vacuum), and the residue was taken up in CH2C12 and washed with H2O. Drying (Na SO4) and concentration left the crude product as an off-white solid, which was reconcentrated from xylenes to remove residual DMF. The aqueous washings were combined and extracted with CHCI3. The combined CHCI3 layers were dried (Na2SO4), concentrated, and reconcentrated from xylenes to provide additional crude product. The crude products were combined and chromatographed (silica gel, 20% MeOH/CHCl3) to give the title compound as a colorless solid (205.2 mg, 77%): TLC R 0.39 (20% MeOH/CHCl3); ]H NMR (250 MHz, CDC13) δ 7.05- 7.15 (m, 2H), 6.52 (d, J=8.8 Hz, IH), 5.44 (d, J=16.4 Hz, IH), 5.00-5.12 (m, IH), 4.10-4.70 (m, 2H), 4.40 (d, J=5.1 Hz, IH), 3.75 (s, 3H), 3.73 (d, J=16.4 Hz, 1 H, partially obscured by the δ 3.75 resonance), 3.08 (s, 3H), 2.40-3.20 (m, 9H), 1.35- 2.10 (m, 10H); IR (CHCI3) 3400, 2930, 1731, 1669, 1613, 1439, 1282 cm"1; MS (ES) m/e 443.2 (M+H)+. b) (±)-4-Methyl-3-oxo-7-[l-[4-(l-piperidinyl)piperidinyl]carbonyl]-2,3,4,5- tetrahydro- 1 H- 1 ,4-benzodiazepine-2-acetic acid
A mixture of methyl (±)-4-methyl-3-oxo-7-[l-[4-(l- piperidinyl)piperidinyl]carbonyl]-2,3,4,5-tetrahydro- IH- 1 ,4-benzodiazepine-2- acetate (205.2 mg, 0.48 mmol), 1.0 N NaOH (1.4 mL, 1.4 mmol), and MeOH (4.8 mL) was stirred at 35-40°C for 19.5 h, then was concentrated to dryness. The residue was dissolved in H2O (2-3 mL), cooled to 0°C, and acidified with TFA. Concentration left a residue which was purified by chromatography (ODS, step gradient, 12% CH3CN/H2O-0.1% TFA, 15% CH3CN/H2O-0.1% TFA).
Concentration and lyophilization gave the title compound as a colorless powder (229.1 mg, 78%): HPLC k' 2.9 (PRP-1®, 12% CH3CN/H2O-0.1 % TFA); tø NMR (400 MHz, CD3OD) δ 7.11 -7.18 (m, 2H), 6.61 (d, J=9.0 Hz, IH), 5.58 (d, J=16.6 Hz, IH), 5.20 (dd, J=9.0, 5.1 Hz, IH), 4.25-4.68 (m, 2H), 3.88 (d, J=16.6 Hz, IH), 3.41-3.56 (m, 3H), 3.04 (s, 3H), 2.88-3.16 (m, 4H), 2.94 (dd, J=16.7, 9.0 Hz, IH), 2.65 (dd, J=16.7, 5.1 Hz, IH), 1.43-2.20 (m, 10H); MS (ES) m/e 429.2 (M+H)+. Anal. Calcd for C23H32N4O4 • 1.5 CF3CO2H • 0.5 H2O: C, 51.31: H, 5.71; N, 9.21. Found: C, 51.51; H, 5.90; N, 9.29.
Example 12
Preparation of (± -4-methyl-3-oxo-7-ll -[4-(2-pyridiny piperazinyllcarbonyll- 2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid
a) Methyl (±)-4-methyl-3-oxo-7-[l-[4-(2-pyridinyl)piperazinyl]carbonyl]-2,3,4,5- tetrahydro- 1 H- 1 ,4-benzodiazepine-2-acetate
EDC (137.6 mg, 0.72 mmol) was added to a solution of methyl (±)-7- carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (175.4 mg, 0.6 mmol), 4-(2-pyridinyl)piperazine (0.11 mL, 0.72 mmol), HOBT H O (97.3 mg, 0.72 mmol), and diisopropylethylamine (0.21 mL, 1.2 mmol) in anhydrous DMF (3 mL) at RT. After 18.5 h, the mixture was concentrated on the rotavap (high vacuum), and the residue was partitioned between 10% aqueous Na2CO3 and CHC13. The layers were separated and the aqueous layer was extracted with CHC13. The combined CHC13 layers were washed with brine, dried (Na2SO4), and concentrated. The residue was concentrated from 1:1:1 CHCi MeOH/xylenes to remove DMF, then was chromatographed (silica gel, 5% MeOH CHCl3). The impure oily product obtained in this way was dissolved in EtOAc. Crystallization began almost immediately, and the mixture was cooled in ice. The solid was collected by suction filtration and was washed with EtOAc. Drying in high vacuum gave the title compound as a nearly colorless solid (239.6 mg, 91%): mp >250°C; TLC Rf 0.39 (5% MeOH/CHCl ); *H NMR (400 MHz, CDC1 ) δ 8.18-8.25 (m, IH), 7.49-7.59 (m, IH), 7.15-7.23 (m, 2H), 6.65-6.75 (m, 2H), 6.54 (d, J=8.0 Hz, IH), 5.45 (d, J=16.5 Hz, IH), 5.03-5.12 (m, IH), 4.40 (d, J=5.0 Hz, IH), 3.68-3.85 (m, 5H), 3.75 (s, 3H), 3.51-3.68 (m, 4H), 3.09 (s, 3H), 3.00 (dd, J=16.0, 6.6 Hz, IH), 2.68 (dd, J=16.0, 6.5 Hz, IH); MS (ES) m/e 438.2 (M+H)+, 275.0.
b) (±)-4-Methyl-3-oxo-7-[l-[4-(2-pyridinyl)piperazinyl]carbonyl]-2,3,4,5- tetrahydro- IH- 1 ,4-benzodiazepine-2-acetic acid
1.0 N NaOH (0.65 mL, 0.65 mmol) was added dropwise to a suspension of methyl (±)-4-methyl-3-oxo-7-[l-[4-(2-pyridinyl)piperazinyl]carbonyl]-2,3,4,5- tetrahydro-lH-l,4-benzodiazepine-2-acetate (235 mg, 0.54 mmol) in MeOH (5.4 mL) at RT, and the resulting mixture was stirred at 50°C. After 3.5 h, more 1.0 N NaOH (0.65 mL, 0.65 mmol) was added, and warming at 50°C was continued for 0.5 h. The resulting homogeneous solution was stirred at RT for 18.5 h, then was concentrated. The residue was dissolved in H2O (5 mL), and the solution was acidified with TFA. Concentration left a foamy oil which was purified by chromatography (ODS, 12% CH3CN/H2O-0.1 % TFA). Concentration and lyophilization gave the title compound (280 mg, 87%) as a colorless powder: HPLC k* 3.7 (PRP-1®, 12% CH CN/H2O-0.1% TFA); H NMR (400 MHz, CD3OD) δ 7.96-8.10 (m, 2H), 7.37 (d, J=9.1 Hz, IH), 7.28-7.38 (m, 2H), 7.02 (app t, IH), 6.64 (d, J=9.1 Hz, IH), 5.58 (d, J=16.5 Hz, IH), 5.21 (dd, J=9.0, 5.1 Hz, IH), 3.68-3.97 (m, 9H), 3.04 (s, 3H), 2.94 (dd, J=16.8, 9.0 Hz, IH), 2.66 (dd, J=16.8, 5.1 Hz, IH); MS (ES) m e 424.2 (M+H)+. Anal. Calcd for C22H25N5O4 • 1.5 CF CO2H: C, 50.51: H, 4.49; N, 11.78. Found: C, 50.42; H, 4.78; N, 11.77.
Example 13
Preparation of .±.-4-methyl-3-oxo-7-π -r4-(phenylmethyl piperazinyllcarbonyl1- 2.3.4.5-tetrahydro-lH-1.4-benzodiazepine-2-acetic acid a) Methyl (±)-4-methyl-3-oxo-7-[l-[4-(phenylmethyl)piperazinyl]carbonyl]- 2,3,4,5-tetrahydro-lH- 1 ,4-benzodiazepine-2-acetate
Methyl (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro- IH- 1 ,4- benzodiazepine-2-acetate (292.3 mg, 1.0 mmol) was refluxed with thionyl chloride (lO mL) for 20 min, and the yellow solution was concentrated. The residue was concentrated from dry toluene (5 mL), then was taken up in dry CH C1 (10 mL) and cooled to 0°C under argon. 1-benzylpiperazine (0.70 mL, 4 mmol) was added all at once, and after 5 min, the light yellow solution was warmed to RT. The reaction was stirred for 0.5 h, then was washed sequentially with 1.0 N NaOH and H2O. Drying (MgSO4), concentration, and chromatography ( silica gel, 10%
MeOH in 1:1 EtOAc/CHCl3) gave the title compound as an off-white foam (344.4 mg, 76%): TLC Rf 0.47 (10% MeOH in 1:1 EtOAc/CHCl3); *H NMR (400 MHz, CDC1 ) δ 7.22-7.40 (m, 5H), 7.08-7.20 (m, 2H), 6.50 (d, J=8.8 Hz, IH), 5.43 (d, J=16.4 Hz, IH), 5.02-5.10 (m IH), 4.37 (br d, J=5.1 Hz, IH), 3.45-3.85 (m, 7H), 3.74 (s, 3H), 3.07 (s, 3H), 2.98 (dd, J=16.1, 6.7 Hz, IH), 2.66 (dd, J=16.1, 6.4 Hz, IH); FTIR (CCI4) 1740, 1672, 1630, 1611, 1456, 1437, 1296 cm"1; MS (ES) m e 451.2 (M+H)+.
b) (±)-4-Methyl-3-oxo-7-[l-[4-(phenylmethyl)piperazinyl]carbonyl]-2,3,4,5- tetrahydro- 1 H- 1 ,4-benzodiazepine-2-acetic acid
1.0 N LiOH (0.91 mL, 0.91 mmol) was added to a solution of methyl (±)-4- methyl-3-oxo-7-[l-[4-(phenylmethyl)piperazinyl] carbonyl]-2,3,4,5-tetrahydro-lH- l,4-benzodiazepine-2-acetate (344.4 mg, 0.76 mmol) in THF (3.8 mL) and H2O (2.9 mL) at 0°C. The resulting bright yellow solution was stirred at RT for 15 h, then was acidified with TFA (0.23 mL) and concentrated to dryness.
Chromatography (ODS, 20% CH3CN/H2O-0.1% TFA), concentration, and lyophilization gave the title compound as a colorless powder (349.9 mg, 77%): HPLC k' 1.6 (PRP-1®, 20% CH3CN/H2O-0.1% TFA); *H NMR (400 MHz, CD3OD) δ 7.43-7.57 (m, 5H), 7.14-7.22 (m, 2H), 6.62 (d, J=9.0 Hz, IH), 5.57 (d, J=16.6 Hz, IH), 5.20 (dd, J=9.0, 5.1 Hz, IH), 4.37 (s, 2H), 3.88 (d, J=16.6 Hz, IH), 3.45-4.30 (m, 2H), 3.15-3.45 (m, 6 H, partially obscured by residual solvent signal), 3.03 (s, 3H), 2.93 (dd, J=16.9, 9.0 Hz, IH), 2.65 (dd, J=16.9, 5.1 Hz, IH); MS (ES) m/e 437.2 (M+H)+. Anal. Calcd for C24H28N4O4 • 1.25 CF3CO2H: C, 53.31; H, 5.28; N, 9.38. Found: C, 53.30; H, 5.42; N, 9.35. Example 14
Preparation of (±)-4-methyl-3-oxo-7-ri-r4-(2-pyrimidinyl)piperazinyllcarbonyll- 2.3.4.5-tetrahvdro-lH-l ,4-benzodiazepine-2-acetic acid
a) Methyl (±)-4-methyl-3-oxo-7-[l-[4-(2-pyrimidinyl)piperazinyl]carbonyl]- 2,3,4,5-tetrahydro- IH- 1 ,4-benzodiazepine-2-acetate
A mixture of methyl (±)-7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH- l,4-benzodiazepine-2-acetate (584 mg, 2.0 mmol), l-(2-pyrimidinyl)piperazine dihydrochloride (522 mg, 2.2 mmol), HOBT H2O (270 mg, 2 mmol), triethylamine (1.0 mL, 7.2 mmol), and EDC (383 mg, 2 mmol) in anhydrous DMF (40 mL) was stirred at RT overnight. The reaction was concentrated in vacuum, and the resulting residue was diluted with 5% K2CO3. CH2C12 extraction, drying (MgSO4), and concentration gave the title compound (0.76 g, 86%): MS (ES) m e 483 (M+H)+.
b) (±)-4-Methyl-3-oxo-7-[l-[4-(2-pyrimidinyl)piperazinyl]carbonyl]-2,3,4,5- tetrahydro- IH- 1 ,4-benzodiazepine-2-acetic acid
Methyl (±)-4-methyl-3-oxo-7-[l-[4-(2-pyrimidinyl)piperazinyl]carbonyl]- 2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (0.7 g, 1.6 mmol) was suspended in MeOH (10 mL) and THF (5 mL), and 1.0 N NaOH (6 mL) were added. The reaction was stirred at RT for 2 d, then was concentrated in vacuum. The residue was diluted with H2O, and the pH was adjusted to 5 to 6 with 1.5 N HC1. Lyophilization gave the title compound (0.186 g, 27%): MS (ES) m e 425 (M+H)+. Anal. Calcd for C2ιH24N6O4 • 2.4 H2O: C, 53.93; H, 6.21 ; N, 17.97. Found: C, 54.25; H, 5.96; N, 17.53.
Example 15
Preparation of 8-..2S-amino-3-phenylpropanoyllamino1-2-methyl-3-oxo-2.3.4.5- tetrahvdro- 1 H-2-benzazepine-4RS-acetic acid
a) Methyl-8-[[2S-(tert-butoxycarbonyl)amino-3-phenylpropanoyl]amino]-2- methyl-3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine-4RS-acetate Methyl (±)-8-amino-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine-
4- acetate was coupled with Boc-L-phenylalanine according to the procedure of Example 5(b). Purification by chromatography (silica gel, l%-5% CH3OH/CH2CI2) gave the title compound as a light yellow foam (99%): JH NMR (CDCI3) δ 7.80 (m, IH), 7.30 (m, 5H), 7.02 (m, 2H), 5.25 (d, J=15.9 Hz, IH), 5.10 (m, IH), 4.45 (m, IH), 3.80 (m, IH), 3.78 (d, J=15.9 Hz, IH), 3.71 (s, 3H), 3.14 (d, J=6.8 Hz, IH), 3.03 (s, 3H), 2.97 (m, 2H), 2.88 (m, IH), 2.40 (dd, J=16.8, 5.4 Hz, IH), 1.43 (s, 9H).
b) 8-[[2S-Amino-3-phenylpropanoyl]amino]-2-methyl-3-oxo-2,3,4,5-tetrahydro- lH-2-benzazepine-4RS-acetic acid
Methyl-8-[[2S-(tert-butoxycarbonyl)amino-3-phenylpropanoyl]amino]-2- methyl-3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine-4(R,S)-acetate was deprotected according to the procedure of Example 20(b) to give the title compound as a light yellow foam (58%): MS (ES) m/e 396(M+H)+. Anal. Calcd for C22H25N3O4 • 1.57 C2F3HO2: C, 52.56; H, 4.66; N, 7.73. Found: C, 52.95; H, 4.90; N, 6.92.
Example 16
Preparation of .±y8-.. r(2-hydroxy-2-phenvDethyl1methylaminolcarbonyll-2- methyl-3-oxo-2.3.4.5-tetrahydro- lH-2-benzazepine-4- acetic acid
a) Methyl (±)-8-[[[(2-hydroxy-2-phenyl)ethyl]methylamino]carbonyl]-2-methyl-3- oxo-2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetate
EDC (230 mg, 1.2 mmole) was added to a stirred solution of methyl (±)-8- carboxy-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetate (1.0 mmol), (±)-α-(methylaminomethyl)benzyl alcohol (1.2 mmol), HOBT H2O (162 mg, 1.2 mmol), and diisopropylethylamine (0.70 mL, 4.0 mmol) in anhydrous
DMF (5 mL) at RT. After 19 hr, the reaction was concentrated on the rotavap (high vacuum), and the residue was partitioned between H2O and EtOAc. The layers were separated and the organic layer was washed with H2O. Drying (MgSO4), concentration, and chromatography (silica gel, l%-3% CH3OH/CH2CI2) gave the title compound as an off-white foam (62%): *H NMR (CDCI3) (mixture of diastereomers) δ 8.62 (d, J=5 Hz), 8.29 (d, J=7.8 Hz), 7.93 (m), 7.81 (m), 7.62 (s), 7.45 (m), 7.18 (d, J=5 Hz), 7.11 (d, J=8.3 Hz), 7.00 (d, J=8.2 Hz), 5.42 (br s), 5.33 (d, J=16), 5.25 (d, J=16 Hz), 3.88 (d, J=16.5 Hz), 3.85 (m), 3.79 (d, J=16.3 Hz), 3.70 (s), 3.69 (s), 3.05 (s), 3.01 (s), 3.00 (m), 2.43 (m), 2.18 (s). b) (±)-8-[[[(2-Hydroxy-2-phenyl)ethyl]methylamino]carbonyl]-2-methyl-3-oxo- 2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetic acid
Methyl (±)-8-[[[(2-hydroxy-2-phenyl)ethyl]methylamino]carbonyl]-2- methyl-3-oxo-2,3,4,5-tetrahydro- lH-2-benzazepine-4-acetate was saponified according to the procedure of Example 6(b) to give the title compound as a white solid (80%): *H NMR (DMSO-d6) δ 8.12 (m, IH), 7.80 (m, 2H), 7.53 (m, 2H), 7.41 (m, 2H), 5.09 (m, 2H), 4.80 (m, 2H), 3.97 (m, IH), 3.40 (m, 5H), 3.18 (s, 3H), 3.08 (m, IH), 2.87 (m, IH), 2.64 (m, IH), 2.36 (m, IH); MS (ES) m e 411 (M+H)+. Anal. Calcd for C23H26N2O5 • 1.75 H2O: C, 62.50; H, 6.73; N, 6.34. Found: C, 62.60; H, 6.63; N, 6.19.
Example 17
Preparation of (±V7-rrrN-(2-hydroxyethyl -N-methyl1aminolcarbonyll-4-methyl-3- oxo-2.3.4.5-tetrahvdro-lH-l .4-benzodiazepine-2-acetic acid
a) Methyl (±)-7-[[[N-(2-hydroxyethyl)-N-methyl]amino]carbonyl]-4-methyl-3- oxo-2,3,4,5-tetrahydro- IH- 1 ,4-benzodiazepine-2-acetate
EDC (229.4 mg, 1.2 mmol) was added to a stirred solution of methyl (±)-7- carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate
(292.3 mg, 1.0 mmol), 2-(methylamino)ethanol (0.10 mL, 1.2 mmol), HOBT H2O (162.2 mg, 1.2 mmol), and dϋsopropylethylamine (0.35 mL, 2.0 mmol) in anhydrous DMF (5 mL) at RT. After 15.5 h, the reaction was concentrated on the rotavap (high vacuum), and the resulting yellow oil was dissolved in CHCI3. The solution was washed with 10% Na2CO3, and the aqueous was back-extracted with CHCI3. The combined organic layers were dried (Na2SO4), concentrated, and reconcentrated from xylenes to remove residual DMF. Chromatography (silica gel, 2:2: 1 EtOAc/CHCl3/MeOH) gave the title compound as a colorless oil (336 mg, 96%): TLC Rf 0.46 (2:2:1 EtOAc/CHCl /MeOH); Η NMR (250 MHz, CDCI3) δ 7.15-7.25 (m, 2H), 6.51 (d, J=8.9 Hz, IH), 5.44 (d, J=16.4 Hz, IH), 5.08 (t, J=6.6 Hz, IH), 3.52-3.98 (m, 5H), 3.75 (s, 3H), 3.10 (s, 3H), 3.08 (s, 3H), 3.00 (dd, J=16.0, 6.8 Hz, IH), 2.67 (dd, J=16.0, 6.4 Hz, IH); IR (CHCI3) 3060-3540, 1729, 1659, 1612, 1482, 1437, 1402 cm"1; MS (ES) m e 350.0 (M+H)+. b) (±)-7-[[[N-(2-Hydroxyethyl)-N-methyl]amino]carbonyl]-4-methyl-3-oxo- 2,3 ,4,5-tetrahydro- 1 H- 1 ,4-benzodiazepine-2-acetic acid
1.0 N NaOH (1.4 mL, 1.4 mmol) was added dropwise to a solution of methyl (±)-7-[[[N-(2-hydroxyethyl)-N-methyl]amino]carbonyl]-4-methyl-3-oxo- 2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (336.3 mg, 0.96 mmol) in MeOH (4.8 mL) at 0°C, and the resulting solution was stirred at RT. After 16 h, the reaction was concentrated, and the residue was purified by chromatography (ODS, 30% MeOH/H2O). The fractions containing the product were combined, concentrated to dryness, and the residue was repurified by ODS chromatography (15% MeOH/H2O). Concentration and lyophilization gave the title compound as a colorless powder (231 mg, 64%): HPLC k' 3.7 (PRP-1®, 10% CH3CN/H2O-0.1% TFA); H NMR (400 MHz, CD3OD) δ 7.11-7.20 (m, 2H), 6.59 (d, J=8.1 Hz, IH), 5.59 (d, J=16.5 Hz, IH), 5.15 (t, J=7.0 Hz, IH), 3.85 (d, J=16.5 Hz, IH), 3.45-3.85 (m, 4H), 3.10 (br s, 3H), 3.03 (s, 3H), 2.79 (dd, J=15.5, 7.5 Hz, IH), 2.45 (dd, J=15.5, 6.4 Hz, IH); MS (ES) m/e 358.0 (M+Na)+, 336.0 (M+H)+. Anal. Calcd for Cι6H2oN3O5Na • H2O: C, 51.20: H, 5.91; N, 11.19. Found: C, 51.04; H, 6.04; N, 11.14.
Example 18
Preparation of (± -8-rr(2-(2-pyridinylamino acetyllamino1-2-methyl-3-oxo-2.3.4.5- tetrahydro- 1 H-2-benzazepine-4- acetic acid
a) Methyl 2-(2-pyridinyl)acetate hydrochloride A solution of 2-(2-pyridinyl)acetic acid (0.50 g, 3 mmol; prepared according to J. Prakt. Chem. 1961, 285, 118) in MeOH (20 mL) was saturated with HC1 gas at 0°C, then was allowed to warm to RT. After stirring overnight, the reaction was concentrated under vacuum to afford the title compound (0.54 g, 100%) as a colorless solid: *H NMR (CDC13) δ 8.90 (br s, IH), 7.89 (m, 2H), 6.89 (t, J=6.5 Hz, IH), 6.79 (d, J=8 Hz, IH), 4.21 (m, 2H), 3.81 (s, 3H).
b) Methyl 2-(N-tert-butoxycarbonyl-N-2-pyridinyl)aminoacetate
Methyl 2-(2-pyridinyl)aminoacetate hydrochloride (1.0 g, 5 mmol) was partitioned between EtOAc and 10% K2CO3. The organic layer was washed with brine, dried (MgSO4), and concentrated. The residue was dissolved in CH2C12 (10 mL), and di-tert-butyl dicarbonate (1.2 g, 5 mmol) was added. The reaction was stirred at RT under argon overnight, then was concentrated. Chromatography on silica gel (l%-5% CH3OH/CH2CI2) gave the title compound as a pale yellow oil (0.89 g, 68%): *H NMR (CDCI3) δ 8.31 (dd, J=4.8, 1.5 Hz, IH), 7.84 (d, J=4.8 Hz, IH), 7.67 (m, IH), 7.00 (m, IH), 4.73 (s, 2H), 3.75 (s, 3H), 1.52 (s, 9H).
c) 2-(N-tert-butoxycarbonyl-N-2-pyridinyl)aminoacetic acid
Methyl 2-(N-tert-butoxycarbonyl-N-2-pyridinyl)aminoacetate was saponified according to the procedure of Example 6(b) to give the title compound (74%) as a white solid.
d) Methyl (±)-8-[[2-(N-tert-butoxycarbonyl-N-2-pyridinyl)aminoacetyl]amino]-2- methyl-3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetate
Methyl (±)-8-amino-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine- 4-acetate was coupled with 2-(N-tert-butoxycarbonyl-N-2-pyridinyl)aminoacetic acid according to the procedure of Example 5(b). Purification by silica gel chromatography ( 1 %-3% CH3OH/CH2CI2) gave the title compound as a light yellow foam (56%): JH NMR (CDCI3) ' 9.72 (s, IH), 8.45 (d, J=4.2 Hz, IH), 7.89 (t, J=4.2 Hz, IH), 7.80 (d, J=8.3 Hz, IH), 7.50 (s, IH), 7.26 (m, 2H), 7.03 (d, J=8.4 Hz, IH), 5.28 (d, J=16.4 Hz, IH), 4.66 (s, 2H), 3.82 (d, J=16.4 Hz, IH), 3.80 (m, IH), 3.71 (s, 3H), 3.04 (s, 3H), 3.00 (m, 2H), 2.90 (m, IH), 2.41 (dd, J=16.8, 5.2 Hz, IH), 1.52 (s, 9H).
e) (±)-8-[[(2-(2-pyridinylamino)acetyl]amino]-2-methyl-3-oxo-2,3,4,5-tetrahydro- lH-2-benzazepine-4-acetic acid
Methyl (±)-8-[[2-(N-tert-butoxycarbonyl-N-2- pyridinyl)aminoacetyl]amino]-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2- benzazepine-4-acetate was deprotected according to the procedure of Example 20(b). Purification by chromatography (ODS, 10% CH3CN/H2O-0.1 % TFA) followed by lyophilization gave the title compound as an off-white powder (23%): *H NMR (CD3OD) δ 7.99 (m, IH), 7.90 (d, J=6.4 Hz, IH), 7.48 (d, J=2 Hz, IH), 7.41 (dd, J=8.3, 2 Hz, IH), 7.15 (d, J=9.2 Hz, IH), 7.11 (d, J=8.4 Hz, IH), 6.98 (m, IH), 5.35 (d, J=16.4 Hz, IH), 4.32 (s, 2H), 3.94 (d, J=16.4 Hz, IH), 3.90 (m, IH), 3.07 (dd, J=17, 4.3 Hz, IH), 2.70 (m, 2H), 2.45 (dd, J=17, 5 Hz, IH); MS (ES) m/e 383.2(M+H)+. Anal. Calcd for C20H22N4O4 • 1.5 C2F3HO2 • 0.5 H2O: C, 49.11 ; H, 4.39; N, 9.96. Found: C, 49.23; H, 4.27; N, 10.07. Example 19
Preparation of (±V4-methyl-3-oxo-7-rr(2-phenylaminoethyl.aminolcarbonyll- 2.3.4.5-tetrahvdro-lH-l .4-benzodiazepine-2-acetic acid
a) Methyl (±)-4-methyl-3-oxo-7-[[(2-phenylaminoethyl)amino]carbonyl]-2,3,4,5- tetrahydro- IH- 1 ,4-benzodiazepine-2-acetate
Following the procedure of Example 14(a), except substituting N- phenylethylenediamine for the l-(2-pyrimidinyl)piperazine dihydrochloride, the title compound was prepared (78%): MS (ES) m/e 411 (M+H)+.
b) (±)-4-Methyl-3-oxo-7-[[(2-phenylaminoethyl)amino]carbonyl]-2,3,4,5- tetrahydro- IH- 1 ,4-benzodiazepine-2-acetic acid
Following the procedure of Example 14(b), methyl (±)-4-methyl-3-oxo-7- [[(2-phenylaminoethyl)amino]carbonyl]-2,3,4,5-teμahydro-lH-l,4-benzodiazepine- 2-acetate was saponified to give the title compound (24%): MS (ES) m/e 397 (M+H)+. Anal. Calcd for C2ιH24N4O4 • 1.5 CF3CO2H • 1.5 H2O: C, 48.49; H, 4.83; N, 9.42. Found: C, 48.41; H, 4.81; N, 9.40.
Example 20
Preparation of (±.-8-r.2-aminoacetyl.aminol-2-methyl-3-oxo-2.3.4.5-tetrahydro- lh-2-benzazepine-4- acetic acid
a) Methyl (±)-8-[(2-[tert-butoxycarbonyl]aminoacetyl)amino]-2-methyl-3-oxo- 2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetate
Methyl (±)-8-amino-2-methyl-3-oxo-2,3,4,5-tetrahydro- 1 H-2-benzazepine- 4- acetate was coupled with Boc-glycine according to the procedure of example 5(b). Purification by chromatography (silica gel, 2%-5% CH3OH/CH2CI2) gave the title compound as a pale yellow foam (55%): lU NMR (CDCI3) δ 8.22 (br s, IH), 7.48 (s, IH), 7.20 (d, J=8.3 Hz, IH), 7.04 (d, J=8.3 Hz, IH), 5.27 (d, J=16.6 Hz, IH), 5.25 (br s, IH), 3.92 (d, J=5.4 Hz, 2H), 3.82 (m, IH), 3.80 (d, J=16.6 Hz, IH), 3.71 (s, 3H), 3.03 (s, 3H), 2.90 (m, 3H), 2.41 (dd, J=16.8, 5.5 Hz, IH), 1.48 (s, 9H). b) (±)-8-[(2-Aminoacetyl)amino]-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH- benzazepine-2-acetic acid
Methyl (±)-8-[(2-[tert-butoxycarbonyl]aminoacetyl)amino]-2-methyl-3-oxo- 2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetate was saponified according to the procedure of example 6(b). The resulting product was stirred in 1 : 1 CH2CI2/TFA for 2 h, then was concentrated. Purification by chromatography (ODS, 10% CH3CN/H2O-0.1% TFA) followed by lyophilization gave the title compound as a white powder (76%): H NMR (DMSO-d6) δ 8.10 (br s, 3H), 7.43 (d, J=8.2 Hz, IH), 7.39 (s, IH), 7.10 (d, J=8.2 Hz, IH), 5.26 (d, J=16.1 Hz, IH), 3.91 (d, J=16.1 Hz, IH), 3.76 (m, 3H), 3.03 (dd, J=16, 2 Hz, IH), 2.88 (s, 3H), 2.65 (m, 2H), 2.34 (dd, J=16, 2 Hz, IH); MS (ES) m/e 306 (M+H)+. Anal. Calcd for C15H19N3O4 • 1.5 C2HF3O2 • 0.5 H2O: C, 44.54; H, 4.47; N, 8.66. Found: C, 44.76; H, 4.47; N, 8.43.
Example 21
Preparation of (+/-')-8-I(3-aminopropanoyDaminol-2-methyl-3-oxo-2.3.4.5- tetrahvdro- 1 H-2-benzazepine-4-acetic acid
a) Methyl (±)-8-[[3-[(tert-butoxycarbonyl)amino]propanoyl]amino]-2-methyl-3- oxo-2,3,4,5-tetrahydro-lH-2-benzazepine-4- acetate
Methyl (±)-8-amino-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine- 4-acetate was coupled with Boc-β-alanine according to the procedure of Example 5(b). Purification by chromatography on silica gel gave the title compound (87%) as a light yellow foam: *H NMR (CDCI3) δ 8.20 (br s, IH), 7.48 (s, IH), 7.20 (d, J=8.3 Hz, IH), 7.04 (d, J=8.3 Hz, IH), 5.27 (d, J=16.6 Hz, IH), 3.92 (m, 3H), 3.80 (d, J=16.6 Hz, IH), 3.70 (s, 3H), 3.01 (s, 3H), 2.90 (m, 5H), 2.48 (dd, J=16.8, 5.5 Hz, IH), 1.48 (s, 9H).
b) (±)-8-[(3-Aminopropanoyl)amino-2-methyl-3-oxo-2,3,4,5-tetrahydro- 1H-2- benzazepine-4-acetic acid
Methyl (±)-8-[[3-[(tert-butoxycarbonyl)amino]propanoyl]amino]-2-methyl- 3-oxo-2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetate was deprotected according to the procedure of Example 20(b). Purification by recrystallization (CH3OH/EtOAc) gave the title compound as a white solid (45%): NMR
(DMSO-d6) δ 7.47 (s, IH), 7.37 (d, J=8.3 Hz, IH), 7.03 (d, J=8.3 Hz, IH), 5.23 (d, J=16.3 Hz, IH), 3.85 (d, J=16.3 Hz, IH), 3.70 (m, IH), 2.98 (m, 2H), 2.87 (s, 3H), 2.65 (m, 3H), 2.30 (dd, J=16, 6.8 Hz, IH); MS (ES) m/e 320 (M+H)+. Anal. Calcd for C16H21N3O4 • .5 C2F3HO2 • -5 H2O: C, 52.37; H, 5.95; N, 10.78. Found: C, 52.29; H, 5.97; N, 10.78.
Example 22
Preparation of ■+.-4-methyl-3-oxo-7-irr.3-pyridinyl.methyllaminolcarbonyll- 2.3.4.5-tetrahvdro-lH-1.4-benzodiazepine-2-acetic acid
a) Methyl (±)-4-methyl-3-oxo-7-[[[(3-pyridinyl)methyl]amino]carbonyl]-2,3,4,5- tetrahydro- 1 H- 1 ,4-benzodiazepine-2-acetate
EDC (229.4 mg, 1.2 mmol) was added to a solution of methyl (±)-7- carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (292.3 mg, 1.0 mmol), 3-(aminomethyl)pyridine (0.122 mL, 1.2 mmol), HOBT H2O (162.2 mg, 1.2 mmol), and diisopropylethylamine (0.35 mL, 2.0 mmol) in anhydrous DMF (5 mL) at RT. After 23.5 h, the reaction was concentrated on the rotavap (high vacuum), and the residue was partitioned between 10% aqueous Na2CO3 and CHC13. This caused a solid to precipitate. The layers were separated and the aqueous layer was extracted exhaustively with CHCI3 until all solids had dissolved. The combined CHC13 layers were diluted with CHC13, washed with 10% Na CO3, dried (MgSU4), and concentrated. Crystallization of the residue from EtOAc gave impure title compound. The mother liquors were concentrated, combined with the recrystallized residue and chromatographed (silica gel, 10% MeOH/CHCl3). The title compound was obtained as a colorless solid (341 mg, 89%): TLC Rf 0.37 (10% MeOH/CHCl3); *H NMR (250 MHz, CDC13) δ 8.58-8.68 (m, IH), 8.47-8.57 (m, IH), 7.72-7.81 (m, IH), 7.54 (d, J=2.1 Hz, IH), 7.45 (dd, J=8.5, 2.1 Hz, IH), 7.31 (dd, J=7.7, 4.8 Hz, IH), 6.44-6.63 (m, 2H), 5.45 (d, J=16.4 Hz, IH), 5.04-5.15 (m, IH), 4.64 (d, J=5.9 Hz, 2H), 4.55 (br d, J=4.5 Hz, IH), 3.76 (d, J=16.4 Hz, IH), 3.75 (s, 3H), 3.07 (s, 3H), 2.99 (dd, J=16.0, 6.7 Hz, IH), 2.67 (dd, J=16.0, 6.4 Hz, IH); MS (ES) m/e 383.2 (M+H)+.
b) (±)-4-Methyl-3-oxo-7-[[[(3-pyridinyl)methyl]amino]carbonyl]-2,3,4,5- tetrahydro- IH- 1 ,4-benzodiazepine-2-acetic acid A mixture of methyl (±)-4-methyl-3-oxo-7-[[[(3-pyridinyl)methyl]amino] carbonyl]-2,3,4,5-tetrahydro-lH-l,4-benzodiazepine-2-acetate (161.7 mg, 0.42 mmol), 1.0 N NaOH (1.3 mL, 1.3 mmol), and MeOH (4.2 mL) was stirred at 40°C for 3 h, then at RT overnight. The resulting solution was concentrated, and the residue was dissolved in H2O and CH3CN. The solution was acidified to pH 1 with TFA and was concentrated. The residue was crystallized from H2O to afford the title compoundas an off-white, crystalline solid (120.9 mg, 60%) : HPLC k' 5.7 (PRP-1®, 8% CH3CN/H2O-0.1% TFA); Η NMR (250 MHz, DMSO-d6) δ 8.60- 8.83 (m, 3H), 8.15 (br d, J=8.0 Hz, IH), 7.75 (dd, J=7.9, 5.3 Hz, IH), 7.49-7.60 (m, 2H), 6.56 (d, J=9.1 Hz, IH), 6.38 (br s, IH), 5.49 (d, J=16.5 Hz, IH), 5.01-5.16 (m, IH), 4.37-4.65 (m, 2H), 3.82 (d, J=16.5 Hz, IH), 2.92 (s, 3H), 2.77 (dd, J=16.7, 9.0 Hz, IH), 2.61 (dd, J=16.7, 4.9 Hz, 1 H, partially obscured by the residual solvent signal); MS (ES) m/e 369.0 (M+H)+. Anal. Calcd for Cι9H20N4O4 • CF3CO2H: C, 52.29: H, 4.39; N, 11.61. Found: C, 52.45; H, 4.40; N, 11.56.
The above description fully discloses how to make and use the present invention. However, the present invention is not limited to the particular embodiments described hereinabove, but includes all modifications thereof within the scope of the following claims. The various references to journals, patents and other publications which are cited herein comprises the state of the art and are incorporated herein by reference as though fully set forth.

Claims

What is claimed is:
1. A compound according to formula (I):
Figure imgf000050_0001
(I) wherein
X-X' is NRi-CH, NC(O)R3-CH, N=C, CR^C, CHRi-CH, O-CH or S-CH;
R1 is H, Ci-6 alkyl or benzyl;
R2 is (CH2)nCO2H;
R3 is H, Cι_6alkyl, Ar-Co_6alkyl, Het-Co-6-alkyl, or C3_6cycloalkyl-Co-6alkyl;
R4 is W-U, Y-(CHR5)m-U or Z-C(O);
R5 and R6 are independently chosen from H, Cι_6alkyl, Ar-Co_6alkyl,
Het-Co-6-alkyl and C3_6cycloalkyl-Co_6alkyl; m is 1 or 2; n is 1 or 2; U is NR!C(O), C(O)NR!, CH=CH, C≡C, CH2-CH2, O-CH2, CH2-O or
CH2OCONR1;
Figure imgf000050_0002
Ra is H, OH, NO2, N(R6)2, CON(R6)2, CH2N(R6)2, or R6HN-C(=NH);
Y is NH2, NHR6, N(R6)2, C(O)N(R6)2, OH, =N-OR6,
Figure imgf000050_0003
Figure imgf000050_0004
Rd is H, N(R!)2, Ci-4alkyl, CON(Rl)2, OH, OR1, or Ar-Co-4alkyl; Re is H, Ci-4alkyl, 2- or 3- pyridinyl, 1-, 2- or 3-piperidinyl, or 2- or 4- pyrimidinyl; and pharmaceutically acceptable salts thereof, provided that R3 is not phenylethyl when R4 is
(3-amidino)phenylaminocarbonyl and X-X' is NH-CH.
2. A compound according to claim 1 which has a binding affinity to the vitronectin receptor relative to the fibrinogen receptor of greater than 3:1.
3. A compound according to claim 1 wherein X-X' is NH-CH or CH2-CH and n is l.
4. A compound according to claim 1 wherein U is NR-^CO.
5. A compound according to claim 1 wherein W is
Figure imgf000051_0001
6. A compound according to claim 1 wherein Z is 1-piperazinyl or 1 -piperidinyl.
7. A compound according to claim 1 wherein R4 is Y-(CH2)mNCH3CO.
8. A compound according to claim 1 wherein Re is H or substituted or unsubstituted phenyl, benzyl, pyridinyl, pyrimidinyl or piperidinyl.
9. A compound according to claim 1 wherein Y is OH or NHR6.
10. A compound selected from the group of: (±)-7-[[(6-Amino-2-pyridinyl)amino]carbonyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro- lH-l,4-benzodiazepine-2-acetic acid;
(+)-8-[[(6-amino-2-pyridinyl)amino]carbonyl]-2-methyl-3-oxo-2,3,4,5-tetrahydro- lH-2-benzazepine-4- acetic acid;
(±)-7-[[(6-amino-3-pyridinyl)amino]carbonyl]-3-oxo-4-(2-phenylethyl)-2,3,4,5- tetrahydro- 1 H- 1 ,4-benzodiazepine-2-acetic acid ;
(±)-l-Acetyl-7-[[(6-amino-2-pyridinyl)amino]carbonyl]-4-methyl-3-oxo-2,3,4,5- tetrahydro- 1 H- 1 ,4-benzodiazepine-2-acetic acid ; (±)-2-methyl-3-oxo-8-[[2-(pyridinyl)carbonyl]amino]-2,3,4,5-tetrahydro-lH-2- benzazepine-4-acetic acid; (±)-8-[(benzyloxycarbonyl)amino]-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2- benzazepine-4-acetic acid; (±)-7-[[[3-(aminoiminomethyl)phenyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5- tetrahydro-lH-l,4-benzodiazepine-2-acetic acid; (±)-7-[[[3-(aminocarbonyl)phenyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5- tetrahydro- IH- 1 ,4-benzodiazepine-2-acetic acid ; (±)-4-methyl-3-oxo-7-[l-(4-phenylpiperazinyl)carbonyl]-2,3,4,5-tetrahydro-lH-
1 ,4-benzodiazepine-2-acetic acid ; (±)-4-methyl-3-oxo-7-[(l-piperazinyl)carbonyl]-2,3,4,5-tetrahydro-lH-l,4- benzodiazepine-2-acetic acid; (±)-4-methyl-3-oxo-7-[l-[4-(l-piperidinyl)piperidinyl]carbonyl]-2,3,4,5-tetrahydro- lH-l,4-benzodiazepine-2-acetic acid;
(±)-4-methyl-3-oxo-7-[l-[4-(2-pyridinyl)piperazinyl]carbonyl]-2,3,4,5-tetrahydro-
1H- 1 ,4-benzodiazepine-2-acetic acid; (±)-4-methyl-3-oxo-7-[l-[4-(phenylmethyl)piperazinyl]carbonyl]-2,3,4,5- tetrahydro- IH- 1 ,4-benzodiazepine-2-acetic acid; (±)-4-methyl-3-oxo-7-[l-[4-(2-pyrimidinyl)piperazinyl]carbonyl]-2,3,4,5- tetrahydro- IH- 1 ,4-benzodiazepine-2-acetic acid; 8-[[2S-amino-3-phenylpropanoyl]amino]-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2- benzazepine-4RS-acetic acid; (±)-8-[[[(2-hydroxy-2-phenyl)ethyl]methylamino]carbonyl]-2-methyl-3-oxo- 2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetic acid;
(±)-7-[[[N-(2-hydroxyethyl)-N-methyl]amino]carbonyl]-4-methyl-3-oxo-2,3,4,5- tetrahydro- 1 H- 1 ,4-benzodiazepine-2-acetic acid; (±)-8-[[(2-(2-pyridinylamino)acetyl]amino]-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-
2-benzazepine-4-acetic acid; (±)-4-methyl-3-oxo-7-[[(2-phenylaminoethyl)amino]carbonyl]-2,3,4,5-tetrahydro-
1 H- 1 ,4-benzodiazepine-2-acetic acid; (±)-8-[(2-aminoacetyl)amino]-2-methyl-3-oxo-2,3,4,5-tetrahydro-lh-2- benzazepine-4-acetic acid; (+/-)-8-[(3-aminopropanoyl)amino]-2-methyl-3-oxo-2,3,4,5-tetrahydro-lH-2- benzazepine-4-acetic acid; and
(±)-4-methyl-3-oxo-7-[[[(3-pyridinyl)methyl]amino]carbonyl]-2,3,4,5-tetrahydro-
1H- 1 ,4-benzodiazepine-2-acetic acid.
11. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
12. A method of inhibiting a vitronectin receptor comprising administering a compound according to claim 1.
13. A method of for treating osteoporosis, atherosclerosis, cancer or restenosis in a mammal comprising administering a compound according to claim 1 and a pharmaceutically acceptable carrier.
14. The use of a compound according to claim 1 in the manufacture of a medicament for osteoporosis, atherosclerosis, cancer or restenosis.
PCT/US1995/008146 1994-06-29 1995-06-29 Vitronectin receptor antagonists WO1996000574A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP95925353A EP0762882A4 (en) 1994-06-29 1995-06-29 Vitronectin receptor antagonists
JP8503418A JPH10504807A (en) 1994-06-29 1995-06-29 Vitronectin receptor antagonist
US09/679,982 US6458784B1 (en) 1994-06-29 2000-10-05 Vitronectin receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26769594A 1994-06-29 1994-06-29
US08/267,695 1994-06-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US48264798A Continuation 1994-06-29 1998-11-10

Publications (1)

Publication Number Publication Date
WO1996000574A1 true WO1996000574A1 (en) 1996-01-11

Family

ID=23019798

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/008146 WO1996000574A1 (en) 1994-06-29 1995-06-29 Vitronectin receptor antagonists

Country Status (4)

Country Link
EP (1) EP0762882A4 (en)
JP (1) JPH10504807A (en)
WO (1) WO1996000574A1 (en)
ZA (1) ZA955391B (en)

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0738150A1 (en) * 1994-01-07 1996-10-23 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
WO1997008145A1 (en) * 1995-08-30 1997-03-06 G.D. Searle & Co. Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists
EP0777657A1 (en) * 1994-08-22 1997-06-11 Smithkline Beecham Corporation Bicyclic compounds
EP0796855A1 (en) 1996-03-20 1997-09-24 Hoechst Aktiengesellschaft Inhibitors of bone resorption and vitronectin receptor antagonists
WO1997036862A1 (en) * 1996-03-29 1997-10-09 G.D. Searle & Co. META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS
EP0820991A2 (en) * 1996-07-24 1998-01-28 Hoechst Aktiengesellschaft Cycloalkyl derivatives as bone resorption inhibitors and vitronectin receptor antagonists
EP0820988A2 (en) * 1996-07-24 1998-01-28 Hoechst Aktiengesellschaft Imino derivatives as bone resorption inhibitors and vitronectin receptor antagonists
WO1998014192A1 (en) * 1996-10-02 1998-04-09 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1998015278A1 (en) * 1996-10-07 1998-04-16 Smithkline Beecham Corporation Method for stimulating bone formation
EP0854145A2 (en) * 1996-12-20 1998-07-22 Hoechst Aktiengesellschaft Vitronectin receptor antagonists, their production and their use
EP0854140A2 (en) 1996-12-20 1998-07-22 Hoechst Aktiengesellschaft Vitronectin receptor antagonists, their production and their use
WO1998046220A1 (en) * 1997-04-14 1998-10-22 Merck & Co., Inc. Combination therapy for the prevention and treatment of osteoporosis
EP0895475A1 (en) * 1995-12-29 1999-02-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
EP0906103A4 (en) * 1995-12-29 1999-04-07
EP0928194A1 (en) * 1996-08-29 1999-07-14 Merck & Co., Inc. Compositions and methods for administering integrin receptor antagonists
US5939412A (en) * 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
EP1007051A1 (en) * 1997-08-04 2000-06-14 Smithkline Beecham Corporation Integrin receptor antagonists
WO2000035488A2 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
WO2000035492A2 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
EP1017387A1 (en) * 1997-09-24 2000-07-12 Smithkline Beecham Corporation Vitronectin receptor antagonist
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
WO2000046215A1 (en) * 1999-02-03 2000-08-10 Merck & Co., Inc. Benzazepine derivatives as alpha-v integrin receptor antagonists
WO2000035887A3 (en) * 1998-12-18 2000-11-16 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6218387B1 (en) 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
US6313119B1 (en) 1998-01-23 2001-11-06 Adventis Pharma Deutschland Gmbh Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
US6322770B1 (en) 1998-03-31 2001-11-27 Dupont Pharmaceuticals Company Indazole vitronectin receptor antagonist pharmaceuticals
WO2001097861A2 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6340679B1 (en) 1999-02-13 2002-01-22 Aventis Pharma Deutschland Gmbh Guanidine derivatives as inhibitors of cell adhesion
WO2002018377A1 (en) * 2000-08-29 2002-03-07 Pharmacia Corporation Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
US6458784B1 (en) 1994-06-29 2002-10-01 Smithkline Beecham Corporation Vitronectin receptor antagonists
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6723727B1 (en) * 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
FR2847254A1 (en) * 2002-11-19 2004-05-21 Aventis Pharma Sa New 4-amino-6-piperidinyl-pyrimidine derivatives are vitronectin receptor antagonists useful e.g. for treating osteoporosis, cancer metastasis, restenosis or retinopathy
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
EP1466615A1 (en) 1998-09-16 2004-10-13 MERCK PATENT GmbH Pharmaceutical composition
US6825188B2 (en) 1996-10-02 2004-11-30 Smithkline Beecham Corporation Vitronectin receptor antagonists
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2005120477A2 (en) 2004-06-07 2005-12-22 Merck & Co., Inc. N- (2-benzyl) -2-phenylbutanamides as androgen receptor modulators
WO2007084670A2 (en) 2006-01-18 2007-07-26 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
WO2008087025A2 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
WO2009063990A1 (en) 2007-11-16 2009-05-22 Ube Industries, Ltd. Benzazepinone compound
WO2010136168A2 (en) 2009-05-25 2010-12-02 Merck Patent Gmbh Continuous administration of integrin ligands for treating cancer
US7846932B2 (en) 2004-05-18 2010-12-07 Galapagos Sas Methods for the use of pyrimidine derivatives which are antagonists of vitronectin receptor
EP2292251A1 (en) 2001-04-24 2011-03-09 Merck Patent GmbH Combination therapy using anti-angiogenic agents and TNF-alpha
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000095A2 (en) * 1991-06-28 1993-01-07 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
WO1993008174A1 (en) * 1991-10-18 1993-04-29 Genentech, Inc. NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPIIbIIIa RECEPTOR
WO1994014776A2 (en) * 1992-12-21 1994-07-07 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004534A1 (en) * 1993-08-06 1995-02-16 Smithkline Beecham Corporation Endothelin receptor antagonists
MA23420A1 (en) * 1994-01-07 1995-10-01 Smithkline Beecham Corp BICYCLIC FIBRINOGEN ANTAGONISTS.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000095A2 (en) * 1991-06-28 1993-01-07 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
WO1993008174A1 (en) * 1991-10-18 1993-04-29 Genentech, Inc. NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPIIbIIIa RECEPTOR
WO1994014776A2 (en) * 1992-12-21 1994-07-07 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC AND MEDICINAL CHEMISTRY, Volume 2, Number 9, issued 1994, BONDINELL et al., "Design of a Potent and Orally Active Nonpeptide Platelet Fibrinogen Receptor (GPIIb/IIIa) Antagonist", pages 897-908. *
JOURNAL OF AMERICAN CHEMICAL SOCIETY, Volume 115, Number 19, issued September 1993, KU et al., "Direct Design of a Potent Non-Peptide Fibrinogen Receptor Antagonist Based on the Structure and Conformation of a Highly Constrained Cyclic RGD Peptide", pages 8861-8862. *
JOURNAL OF MEDICINAL CHEMISTRY, Volume 38, Number 1, issued January 1995, KU et al., "Potent Non-Peptide Fibrinogen Receptor Antagonists Which Present an Alternative Pharmacophore", pages 9-12. *
See also references of EP0762882A4 *
TETRAHEDRON LETTERS, Volume 36, Number 3, issued 1995, MILLER et al., "Synthesis of a 2-Benzazepine Analog of a Potent, Nonpeptide GPIIb/IIIa Antagonist", pages 373-376. *

Cited By (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127359A (en) * 1991-06-28 2000-10-03 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US5939412A (en) * 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
EP0738150A4 (en) * 1994-01-07 1997-03-19 Smithkline Beecham Corp Bicyclic fibrinogen antagonists
US6117866A (en) * 1994-01-07 2000-09-12 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
EP0738150A1 (en) * 1994-01-07 1996-10-23 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US6458784B1 (en) 1994-06-29 2002-10-01 Smithkline Beecham Corporation Vitronectin receptor antagonists
EP0777657A1 (en) * 1994-08-22 1997-06-11 Smithkline Beecham Corporation Bicyclic compounds
EP0777657A4 (en) * 1994-08-22 1997-07-16
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
US6831199B1 (en) 1995-08-30 2004-12-14 G. D. Searle & Co. Pyrimidine compounds and derivatives thereof
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
US6028223A (en) * 1995-08-30 2000-02-22 G. D. Searle & Co. Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid compounds and derivatives thereof
WO1997008145A1 (en) * 1995-08-30 1997-03-06 G.D. Searle & Co. Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists
EP0906103A4 (en) * 1995-12-29 1999-04-07
EP0895475A1 (en) * 1995-12-29 1999-02-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
US6159964A (en) * 1995-12-29 2000-12-12 Smithkline Beecham Corporation Vitronectin receptor antagonists
EP0906103A1 (en) * 1995-12-29 1999-04-07 Smithkline Beecham Corporation Vitronectin receptor antagonists
EP0895475A4 (en) * 1995-12-29 2000-08-23 Smithkline Beecham Corp Vitronectin receptor antagonists
US6620820B2 (en) 1996-03-20 2003-09-16 Hoechst Aktiengesellschaft Inhibitors of bone reabsorption and antagonists of vitronectin receptors
EP0796855A1 (en) 1996-03-20 1997-09-24 Hoechst Aktiengesellschaft Inhibitors of bone resorption and vitronectin receptor antagonists
WO1997036862A1 (en) * 1996-03-29 1997-10-09 G.D. Searle & Co. META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS
US6399620B1 (en) 1996-07-24 2002-06-04 Aventis Pharma S.A. Cycloalkyl derivatives as inhibitors of bone resporption and vitronectin receptor antagonists
EP0820988A2 (en) * 1996-07-24 1998-01-28 Hoechst Aktiengesellschaft Imino derivatives as bone resorption inhibitors and vitronectin receptor antagonists
US6005117A (en) * 1996-07-24 1999-12-21 Hoechst Aktiengesellschaft Imino compounds, process for their preparation and their use as victronectin antagonists
US7348333B2 (en) 1996-07-24 2008-03-25 Aventis Pharma S.A. Cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
EP0820988A3 (en) * 1996-07-24 2000-05-17 Hoechst Aktiengesellschaft Imino derivatives as bone resorption inhibitors and vitronectin receptor antagonists
EP0820991A3 (en) * 1996-07-24 2000-05-17 Hoechst Aktiengesellschaft Cycloalkyl derivatives as bone resorption inhibitors and vitronectin receptor antagonists
EP0820991A2 (en) * 1996-07-24 1998-01-28 Hoechst Aktiengesellschaft Cycloalkyl derivatives as bone resorption inhibitors and vitronectin receptor antagonists
EP0928194A1 (en) * 1996-08-29 1999-07-14 Merck & Co., Inc. Compositions and methods for administering integrin receptor antagonists
EP0928194A4 (en) * 1996-08-29 2001-01-17 Merck & Co Inc Compositions and methods for administering integrin receptor antagonists
US6825188B2 (en) 1996-10-02 2004-11-30 Smithkline Beecham Corporation Vitronectin receptor antagonists
AU733417B2 (en) * 1996-10-02 2001-05-17 Smithkline Beecham Corporation Vitronectin receptor antagonists
KR100589578B1 (en) * 1996-10-02 2006-06-15 스미스클라인 비참 코포레이션 Vitronectin Receptor Antagonist
JP2001501936A (en) * 1996-10-02 2001-02-13 スミスクライン・ビーチャム・コーポレイション Vitronectin receptor antagonist
CN1114403C (en) * 1996-10-02 2003-07-16 史密丝克莱恩比彻姆公司 Vitronectin receptor antagonists
CZ299076B6 (en) * 1996-10-02 2008-04-16 Smithkline Beecham Corporation Vitronectin derivatives
WO1998014192A1 (en) * 1996-10-02 1998-04-09 Smithkline Beecham Corporation Vitronectin receptor antagonists
JP2010006838A (en) * 1996-10-02 2010-01-14 Smithkline Beecham Corp Vitronectin receptor antagonist
EA002419B1 (en) * 1996-10-02 2002-04-25 Смитклайн Бичам Корпорейшн Vitronectin receptor antagonists
EP0946180A4 (en) * 1996-10-07 2003-07-23 Smithkline Beecham Corp Method for stimulating bone formation
WO1998015278A1 (en) * 1996-10-07 1998-04-16 Smithkline Beecham Corporation Method for stimulating bone formation
EP0946180A1 (en) * 1996-10-07 1999-10-06 Smithkline Beecham Corporation Method for stimulating bone formation
US6218387B1 (en) 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
EP0854145A3 (en) * 1996-12-20 2000-03-22 Hoechst Aktiengesellschaft Vitronectin receptor antagonists, their production and their use
US6723727B1 (en) * 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
EP0854145A2 (en) * 1996-12-20 1998-07-22 Hoechst Aktiengesellschaft Vitronectin receptor antagonists, their production and their use
US6011045A (en) * 1996-12-20 2000-01-04 Hoechst Aktiengesellschaft Vitronectin receptor antagonists, their preparation and their use
US5990145A (en) * 1996-12-20 1999-11-23 Hoechst Aktiengesellschaft Vitronectin receptor antagonists, their preparation and their use
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
EP0854140A2 (en) 1996-12-20 1998-07-22 Hoechst Aktiengesellschaft Vitronectin receptor antagonists, their production and their use
EP0854140A3 (en) * 1996-12-20 2000-03-08 Hoechst Aktiengesellschaft Vitronectin receptor antagonists, their production and their use
WO1998046220A1 (en) * 1997-04-14 1998-10-22 Merck & Co., Inc. Combination therapy for the prevention and treatment of osteoporosis
EP1007051A1 (en) * 1997-08-04 2000-06-14 Smithkline Beecham Corporation Integrin receptor antagonists
EP1007051A4 (en) * 1997-08-04 2001-08-29 Smithkline Beecham Corp Integrin receptor antagonists
EP1017387A4 (en) * 1997-09-24 2004-08-18 Smithkline Beecham Corp Vitronectin receptor antagonist
EP1017387A1 (en) * 1997-09-24 2000-07-12 Smithkline Beecham Corporation Vitronectin receptor antagonist
US6747148B2 (en) 1998-01-23 2004-06-08 Hoechst Marion Roussel Deutschland Gmbh Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
US6313119B1 (en) 1998-01-23 2001-11-06 Adventis Pharma Deutschland Gmbh Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
US7052673B2 (en) 1998-03-31 2006-05-30 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6322770B1 (en) 1998-03-31 2001-11-27 Dupont Pharmaceuticals Company Indazole vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
EP1466615A1 (en) 1998-09-16 2004-10-13 MERCK PATENT GmbH Pharmaceutical composition
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6818201B2 (en) 1998-12-18 2004-11-16 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US7321045B2 (en) 1998-12-18 2008-01-22 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
WO2000035492A2 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6683163B2 (en) 1998-12-18 2004-01-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6689337B2 (en) 1998-12-18 2004-02-10 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6558649B1 (en) 1998-12-18 2003-05-06 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
WO2000035887A3 (en) * 1998-12-18 2000-11-16 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6743412B2 (en) 1998-12-18 2004-06-01 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US7332149B1 (en) 1998-12-18 2008-02-19 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US7090828B2 (en) 1998-12-18 2006-08-15 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511648B2 (en) 1998-12-18 2003-01-28 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
WO2000035492A3 (en) * 1998-12-18 2001-01-18 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
WO2000035488A2 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
WO2000035488A3 (en) * 1998-12-18 2000-11-09 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
US7018611B2 (en) 1998-12-18 2006-03-28 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6232308B1 (en) 1999-02-03 2001-05-15 Merck & Co., Inc. Bezazepine derivatives as αv integrin receptor antagonists
WO2000046215A1 (en) * 1999-02-03 2000-08-10 Merck & Co., Inc. Benzazepine derivatives as alpha-v integrin receptor antagonists
US6340679B1 (en) 1999-02-13 2002-01-22 Aventis Pharma Deutschland Gmbh Guanidine derivatives as inhibitors of cell adhesion
WO2001097861A2 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
WO2001097861A3 (en) * 2000-06-21 2003-02-27 Bristol Myers Squibb Pharma Co Vitronectin receptor antagonist pharmaceuticals
WO2002018377A1 (en) * 2000-08-29 2002-03-07 Pharmacia Corporation Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
EP2292251A1 (en) 2001-04-24 2011-03-09 Merck Patent GmbH Combination therapy using anti-angiogenic agents and TNF-alpha
FR2847254A1 (en) * 2002-11-19 2004-05-21 Aventis Pharma Sa New 4-amino-6-piperidinyl-pyrimidine derivatives are vitronectin receptor antagonists useful e.g. for treating osteoporosis, cancer metastasis, restenosis or retinopathy
KR101140752B1 (en) 2002-11-19 2012-05-03 갈라파고스 엔.브이. Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same
EP2070914A1 (en) 2002-11-19 2009-06-17 Galapagos SAS New antagonist derivatives of the vitronectin receiver, method for preparing same, application of same as medicine and pharmaceutical compositions containing them
US7763621B2 (en) 2002-11-19 2010-07-27 Galapagos Sas Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same
WO2004048375A1 (en) * 2002-11-19 2004-06-10 Proskelia Sas Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same
EP2368891A1 (en) 2004-05-18 2011-09-28 Galapagos SAS Pyrimidines derivatives as antagonists of the vitronectine receptors
US8765766B2 (en) 2004-05-18 2014-07-01 Galapagos Nv Pyrimidine derivatives which are antagonists of the vitronectin receptor
US8133896B2 (en) 2004-05-18 2012-03-13 Galapagos Nv Pyrimidine derivatives which are antagonist of the vitronectin receptor
US7846932B2 (en) 2004-05-18 2010-12-07 Galapagos Sas Methods for the use of pyrimidine derivatives which are antagonists of vitronectin receptor
WO2005120477A2 (en) 2004-06-07 2005-12-22 Merck & Co., Inc. N- (2-benzyl) -2-phenylbutanamides as androgen receptor modulators
WO2007084670A2 (en) 2006-01-18 2007-07-26 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
EP2335733A1 (en) 2006-01-18 2011-06-22 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
EP2338518A1 (en) 2006-01-18 2011-06-29 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
EP2441464A1 (en) 2007-01-18 2012-04-18 Merck Patent GmbH Specific therapy and medicament using integrin ligands for treating cancer
WO2008087025A2 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
EP2578225A1 (en) 2007-07-18 2013-04-10 Merck Patent GmbH Specific Therapy and Medicament Using Integrin Ligands for Treating Cancer
KR20100106391A (en) 2007-11-16 2010-10-01 우베 고산 가부시키가이샤 Benzazepinone compound
WO2009063990A1 (en) 2007-11-16 2009-05-22 Ube Industries, Ltd. Benzazepinone compound
US8377922B2 (en) 2007-11-16 2013-02-19 Ube Industries, Ltd. Benzazepinone compound
WO2010136168A2 (en) 2009-05-25 2010-12-02 Merck Patent Gmbh Continuous administration of integrin ligands for treating cancer
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Also Published As

Publication number Publication date
JPH10504807A (en) 1998-05-12
ZA955391B (en) 1996-02-09
EP0762882A4 (en) 2002-09-11
EP0762882A1 (en) 1997-03-19

Similar Documents

Publication Publication Date Title
EP0762882A1 (en) Vitronectin receptor antagonists
US6239138B1 (en) Vitronectin receptor antagonist
CA2192764C (en) Integrin receptor antagonists
EP0674623B1 (en) Bicyclic fibrinogen antagonists
US6159964A (en) Vitronectin receptor antagonists
WO1996026190A1 (en) Integrin receptor antagonists
EP1007051A1 (en) Integrin receptor antagonists
AU1354097A (en) Vitronectin receptor antagonists
US6117910A (en) Bicyclic fibrinogen antagonists
EP0946180A1 (en) Method for stimulating bone formation
US5977101A (en) Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
EP1027337A1 (en) Integrin receptor antagonists
US6008213A (en) Integrin receptor antagonists
US6458784B1 (en) Vitronectin receptor antagonists
US6458814B1 (en) Vitronectin receptor antagonists
US6403578B1 (en) Bicyclic fibrinogen antagonists
US20010034445A1 (en) Vitronectin receptor antagonists
US20020032187A1 (en) Method for stimulating bone formation
KR100459621B1 (en) Integrin Receptor Antagonists
US20020055499A1 (en) Integrin receptor antagonists
PL191595B1 (en) Antagonistic integrin receptors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: US

Ref document number: 1996 765753

Date of ref document: 19961220

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1995925353

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995925353

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995925353

Country of ref document: EP